aldosterone and Hypertension, Essential studies

Research Excerpts

Excerpt	Relevance	Reference
"Angiotensin II receptor blockers (ARBs) have been widely used to treat hypertension and large-scale clinical studies have shown various benefits."	9.22	Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study). ( Arimoto, M; Hata, H; Osaka, S; Sakino, H; Sezai, A; Shiono, M; Yaoita, H, 2016)
"To study the development of microalbuminuria (MAU) in essential hypertension (EHT), we investigated the association of MAU with central blood pressure (CBP), direct renin concentration (DRC), plasma aldosterone (PA), and uric acid (UA)."	8.31	Central diastolic blood pressure, plasma aldosterone and uric acid are associated with microalbuminuria in essential hypertension: a case-control study. ( Chou, H; Li, J; Li, Y; Shi, L; Wei, M; Yang, N, 2023)
"We investigated the changes of serum PTH levels induced by oral captopril (50 mg) administration in patients with primary essential hypertension (EH) and with primary aldosteronism (PA) caused by bilateral adrenal hyperplasia (BAH) or aldosterone-producing adenoma (APA), the latter before and after adrenalectomy."	7.91	PTH Modulation by Aldosterone and Angiotensin II is Blunted in Hyperaldosteronism and Rescued by Adrenalectomy. ( Iacobone, M; Lenzini, L; Lerco, S; Maiolino, G; Prisco, S; Rossi, GP; Seccia, TM; Torresan, F; Vanderriele, PE, 2019)
" Anthropometric parameters and aldosterone, plasma renin activity, cortisol, cortisone, Homeostasis Model Assessment Insulin Resistance (HOMA-IR), high-sensitivity C-reactive protein, adiponectin, IL-6, plasminogen activator inhibitor type 1 levels and matrix metalloproteinase-9 and matrix metalloproteinase-2 (MMP-9 and MMP-2) activities were measured."	7.83	Cortisol/cortisone ratio and matrix metalloproteinase-9 activity are associated with pediatric primary hypertension. ( Aglony, M; Allende, F; Bancalari, R; Baudrand, R; Campino, C; Carvajal, CA; Fardella, CE; Fuentes, CA; García, H; García, L; Kalergis, AM; Lagos, CF; Loureiro, C; Martinez-Aguayo, A; Sanhueza, S; Solari, S; Tapia-Castillo, A; Valdivia, C; Vecchiola, A, 2016)
"Among patients with essential hypertension, circulating endogenous ouabain and Aldo are typically coelevated and their BP is salt-sensitive."	7.83	Endogenous ouabain and aldosterone are coelevated in the circulation of patients with essential hypertension. ( Brioni, E; Casamassima, N; Hamlyn, JM; Lanzani, C; Manunta, P; Messaggio, E; Simonini, M; Tentori, S; Zagato, L, 2016)
"The objective of this article is to measure serum dehydroepiandrosterone sulfate (DHEA-S) concentration in both genders with primary aldosteronism (PA)."	7.81	Serum dehydroepiandrosterone sulfate concentration is lower in women with primary aldosteronism. ( Chen, AH; Huang, TS; Li, HY; Lin, YH; Wu, VC, 2015)
" Determination of metanephrines by high-pressure liquid chromatography has been well established for the diagnosis of pheochromocytomas, demonstrating high sensitivity and specificity."	7.78	Plasma and urinary metanephrines determined by an enzyme immunoassay, but not serum chromogranin A for the diagnosis of pheochromocytoma in patients with adrenal mass. ( Deutschbein, T; Hinrichs, J; Mann, K; Petersenn, S; Schmidt, H; Unger, N; Walz, MK, 2012)
"Aldosterone has hypertrophic and profibrotic effects on the heart."	5.91	Serum aldosterone effect on left ventricular structure and diastolic function in essential hypertension. ( Al-Hashedi, EM; Juvenal, H; Mohammed, AA; Yu, J; Zhao, X, 2023)
"Essential hypertension is a pivotal risk factor for the development of cardiovascular disease (CVD)."	5.62	Aldosterone hyperreactivity to acute psychosocial stress induction in men with essential hypertension. ( Ehlert, U; Gideon, A; Sauter, C; von Känel, R; Wirtz, PH, 2021)
"Primary aldosteronism is recognized as the most frequent cause of secondary hypertension, and its screening is expected to become a routine evaluation in most patients with hypertension."	5.56	Renin-Angiotensin-Aldosterone System Triple-A Analysis for the Screening of Primary Aldosteronism. ( Buffolo, F; Burrello, J; Domenig, O; Monticone, S; Mulatero, P; Pecori, A; Poglitsch, M; Tetti, M, 2020)
"Aldosterone treatment enhanced mRNA expression of genes associated with inflammation and fibrosis and stimulated differentiation of 3T3-L1 and brown preadipocytes."	5.48	Inflammation and Fibrosis in Perirenal Adipose Tissue of Patients With Aldosterone-Producing Adenoma. ( Fan, C; Guan, M; Tan, W; Wang, L; Wei, Q; Wu, C; Wu, P; Xie, C; Xu, L; Xue, Y; Zhang, H; Zhang, J, 2018)
"Primary aldosteronism is affecting about 10% of hypertensive patients."	5.48	Criteria for diagnosing primary aldosteronism on the basis of liquid chromatography-tandem mass spectrometry determinations of plasma aldosterone concentration. ( Amar, L; Azizi, M; Baffalie, L; Baron, S; Blanchard, A; Faucard, C; Faucon, AL; Houillier, P; Pagny, JY; Travers, S, 2018)
"All primary aldosteronism patients were diagnosed by autonomous aldosterone secretion using confirmatory tests, and then divided into nPA (n = 130) and primary aldosteronism patients with high PAC (hPA: n = 162) using a PAC cutoff level of less than 443 pmol/l (16 ng/dl), representing the normal upper limit of PAC."	5.46	Plasma aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism. ( Hamasaki, T; Hashimoto, K; Hayashi, RD; Kajimoto, Y; Kitamura, T; Kouhara, H; Kurebayashi, S; Mukai, K; Murata, M; Nakao, M; Otsuki, M; Shimomura, I; Takeiri, S; Tamada, D; Yamamoto, T, 2017)
"Aldosterone has hypertrophic and profibrotic effects on the heart."	5.42	Plasma aldosterone and left ventricular diastolic function in treatment-naïve patients with hypertension: tissue-Doppler imaging study. ( Catena, C; Kraigher-Krainer, E; Pieske, B; Pilz, S; Sechi, LA; Tomaschitz, A; Verheyen, N, 2015)
"In 10 patients with primary aldosteronism, median supine ARRP was 298 (range 48-1222) and ARRD 34 (range 2."	5.40	Measurement of plasma renin concentration instead of plasma renin activity decreases the positive aldosterone-to-renin ratio tests in treated patients with essential hypertension. ( Bassani, N; Biganzoli, E; Gritti, A; Lonati, C; Morganti, A, 2014)
"Angiotensin II receptor blockers (ARBs) have been widely used to treat hypertension and large-scale clinical studies have shown various benefits."	5.22	Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study). ( Arimoto, M; Hata, H; Osaka, S; Sakino, H; Sezai, A; Shiono, M; Yaoita, H, 2016)
"This exploratory study reports two plausible loci associated with SBP response to hydrochlorothiazide: TET2, an aldosterone-responsive mediator of αENaC gene transcription; and CSMD1, previously described as associated with hypertension in a case-control study."	5.20	TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. ( Argiolas, G; Barlassina, C; Boerwinkle, E; Braga, D; Carpini, SD; Chapman, AB; Chittani, M; Citterio, L; Condorelli, G; Cooper-Dehoff, RM; Cusi, D; Dominiczak, AF; Donner, KM; Frau, F; Fresu, G; Glorioso, N; Glorioso, V; Gong, Y; Hiltunen, TP; Johnson, JA; Kontula, KK; Lanzani, C; Manunta, P; Melander, O; Ortu, MF; Padmanabhan, S; Piras, DA; Pozzoli, S; Rivera, NV; Salvi, E; Simonini, M; Trimarco, B; Troffa, C; Turner, ST; Velayutham, D; Zaninello, R, 2015)
"To study the development of microalbuminuria (MAU) in essential hypertension (EHT), we investigated the association of MAU with central blood pressure (CBP), direct renin concentration (DRC), plasma aldosterone (PA), and uric acid (UA)."	4.31	Central diastolic blood pressure, plasma aldosterone and uric acid are associated with microalbuminuria in essential hypertension: a case-control study. ( Chou, H; Li, J; Li, Y; Shi, L; Wei, M; Yang, N, 2023)
"We investigated the changes of serum PTH levels induced by oral captopril (50 mg) administration in patients with primary essential hypertension (EH) and with primary aldosteronism (PA) caused by bilateral adrenal hyperplasia (BAH) or aldosterone-producing adenoma (APA), the latter before and after adrenalectomy."	3.91	PTH Modulation by Aldosterone and Angiotensin II is Blunted in Hyperaldosteronism and Rescued by Adrenalectomy. ( Iacobone, M; Lenzini, L; Lerco, S; Maiolino, G; Prisco, S; Rossi, GP; Seccia, TM; Torresan, F; Vanderriele, PE, 2019)
"Among patients with essential hypertension, circulating endogenous ouabain and Aldo are typically coelevated and their BP is salt-sensitive."	3.83	Endogenous ouabain and aldosterone are coelevated in the circulation of patients with essential hypertension. ( Brioni, E; Casamassima, N; Hamlyn, JM; Lanzani, C; Manunta, P; Messaggio, E; Simonini, M; Tentori, S; Zagato, L, 2016)
" Anthropometric parameters and aldosterone, plasma renin activity, cortisol, cortisone, Homeostasis Model Assessment Insulin Resistance (HOMA-IR), high-sensitivity C-reactive protein, adiponectin, IL-6, plasminogen activator inhibitor type 1 levels and matrix metalloproteinase-9 and matrix metalloproteinase-2 (MMP-9 and MMP-2) activities were measured."	3.83	Cortisol/cortisone ratio and matrix metalloproteinase-9 activity are associated with pediatric primary hypertension. ( Aglony, M; Allende, F; Bancalari, R; Baudrand, R; Campino, C; Carvajal, CA; Fardella, CE; Fuentes, CA; García, H; García, L; Kalergis, AM; Lagos, CF; Loureiro, C; Martinez-Aguayo, A; Sanhueza, S; Solari, S; Tapia-Castillo, A; Valdivia, C; Vecchiola, A, 2016)
"Thirty-three consecutive patients with essential hypertension and hypovitaminosis D underwent therapy with cholecalciferol 50 000 IU/week orally for 8 weeks."	3.83	Cholecalciferol treatment downregulates renin-angiotensin system and improves endothelial function in essential hypertensive patients with hypovitaminosid D. ( Bacca, A; Bernini, G; Bruno, RM; Carrara, D; Duranti, E; Ghiadoni, L; Taddei, S, 2016)
"The objective of this article is to measure serum dehydroepiandrosterone sulfate (DHEA-S) concentration in both genders with primary aldosteronism (PA)."	3.81	Serum dehydroepiandrosterone sulfate concentration is lower in women with primary aldosteronism. ( Chen, AH; Huang, TS; Li, HY; Lin, YH; Wu, VC, 2015)
"Urinary 18-hydroxycortisol has been investigated as a marker of aldosterone-producing adenoma (APA)."	3.79	Quantification of urinary 18-hydroxycortisol using LC-MS/MS. ( Chiba, H; Fuda, H; Fujikawa, M; Hui, SP; Ikegawa, S; Jin, S; Kurosawa, T; Sakurai, T; Takahashi, Y; Takeda, S; Wada, N; Yanagisawa, K, 2013)
" Determination of metanephrines by high-pressure liquid chromatography has been well established for the diagnosis of pheochromocytomas, demonstrating high sensitivity and specificity."	3.78	Plasma and urinary metanephrines determined by an enzyme immunoassay, but not serum chromogranin A for the diagnosis of pheochromocytoma in patients with adrenal mass. ( Deutschbein, T; Hinrichs, J; Mann, K; Petersenn, S; Schmidt, H; Unger, N; Walz, MK, 2012)
"Primary aldosteronism is associated with an increased risk of cardiovascular disease and kidney dysfunction compared to essential hypertension."	3.01	The Effect of Aldosterone on Cardiorenal and Metabolic Systems. ( Abe, M; Kobayashi, H; Otsuka, H, 2023)
"Aldosterone has hypertrophic and profibrotic effects on the heart."	1.91	Serum aldosterone effect on left ventricular structure and diastolic function in essential hypertension. ( Al-Hashedi, EM; Juvenal, H; Mohammed, AA; Yu, J; Zhao, X, 2023)
"Essential hypertension is a major disease, mostly with unknown underlying mechanisms."	1.62	Modulation of 11β-hydroxysteroid dehydrogenase functions by the cloud of endogenous metabolites in a local microenvironment: The glycyrrhetinic acid-like factor (GALF) hypothesis. ( Brem, AS; Morris, DJ; Odermatt, A, 2021)
"Patients with primary aldosteronism (PA) have cardiac remodeling due to hemodynamic and non-hemodynamic causes."	1.62	Hemodynamic and Non-Hemodynamic Components of Cardiac Remodeling in Primary Aldosteronism. ( Chang, CC; Chang, YR; Chang, YY; Chen, YL; Chen, ZW; Hung, CS; Lee, BC; Liao, CW; Lin, LC; Lin, YH; Pan, CT; Tsai, CH; Wu, XM, 2021)
"Essential hypertension is a pivotal risk factor for the development of cardiovascular disease (CVD)."	1.62	Aldosterone hyperreactivity to acute psychosocial stress induction in men with essential hypertension. ( Ehlert, U; Gideon, A; Sauter, C; von Känel, R; Wirtz, PH, 2021)
"Primary aldosteronism is recognized as the most frequent cause of secondary hypertension, and its screening is expected to become a routine evaluation in most patients with hypertension."	1.56	Renin-Angiotensin-Aldosterone System Triple-A Analysis for the Screening of Primary Aldosteronism. ( Buffolo, F; Burrello, J; Domenig, O; Monticone, S; Mulatero, P; Pecori, A; Poglitsch, M; Tetti, M, 2020)
"Primary aldosteronism (PA) is hemodynamically independently associated with arterial wall stiffness as assessed by pulse wave velocity (PWV) compared with essential hypertension."	1.51	Aldosterone Induces Vascular Damage. ( Chang, CC; Chen, CH; Chen, ZW; Cheng, HM; Hung, CS; Liao, CW; Lin, YH; Pan, CT; Sung, SH; Wu, VC, 2019)
"Primary aldosteronism is affecting about 10% of hypertensive patients."	1.48	Criteria for diagnosing primary aldosteronism on the basis of liquid chromatography-tandem mass spectrometry determinations of plasma aldosterone concentration. ( Amar, L; Azizi, M; Baffalie, L; Baron, S; Blanchard, A; Faucard, C; Faucon, AL; Houillier, P; Pagny, JY; Travers, S, 2018)
"The diagnosis of primary aldosteronism typically requires at least one confirmatory test."	1.48	Confirmatory Tests for the Diagnosis of Primary Aldosteronism: A Prospective Diagnostic Accuracy Study. ( Bruemmer, D; Cheng, Q; He, W; Hu, J; Li, Q; Luo, T; Ma, L; Mei, M; Peng, B; Qing, H; Song, Y; Wang, Y; Wang, Z; Yang, S; Zhang, S; Zhen, Q, 2018)
"Aldosterone treatment enhanced mRNA expression of genes associated with inflammation and fibrosis and stimulated differentiation of 3T3-L1 and brown preadipocytes."	1.48	Inflammation and Fibrosis in Perirenal Adipose Tissue of Patients With Aldosterone-Producing Adenoma. ( Fan, C; Guan, M; Tan, W; Wang, L; Wei, Q; Wu, C; Wu, P; Xie, C; Xu, L; Xue, Y; Zhang, H; Zhang, J, 2018)
"Primary aldosteronism is associated with a higher incidence of left ventricular (LV) hypertrophy and diastolic dysfunction than essential hypertension."	1.48	Aldosterone induces left ventricular subclinical systolic dysfunction: a strain imaging study. ( Chang, YY; Chen, CW; Chen, ZW; Huang, KC; Hung, CS; Lee, JK; Liao, CW; Lin, LC; Lin, YH; Wu, VC, 2018)
"Vascular function, including reactive hyperemia index (RIH), flow-mediated vasodilation (FMD), and nitroglycerine-induced vasodilation (NID) were evaluated in 52 patients with IHA, 53 patients with aldosterone-producing adenoma (APA), and 52 age-, sex-, and blood pressure-matched patients with essential hypertension (EHT)."	1.48	Microvascular endothelial function is impaired in patients with idiopathic hyperaldosteronism. ( Hashimoto, H; Higashi, Y; Kajikawa, M; Kihara, Y; Kishimoto, S; Maruhashi, T; Matsui, S; Matsumoto, T; Oki, K; Yusoff, FM, 2018)
"A total of 62 primary aldosteronism and 56 essential hypertension patients were enrolled."	1.46	Increased urinary excretion of the epithelial Na channel activator prostasin in patients with primary aldosteronism. ( Castagna, A; Chiariello, C; Chiecchi, L; Morandini, F; Olivieri, O; Pattini, P; Pizzolo, F; Salvagno, G; Zaltron, C; Zorzi, F, 2017)
"All primary aldosteronism patients were diagnosed by autonomous aldosterone secretion using confirmatory tests, and then divided into nPA (n = 130) and primary aldosteronism patients with high PAC (hPA: n = 162) using a PAC cutoff level of less than 443 pmol/l (16 ng/dl), representing the normal upper limit of PAC."	1.46	Plasma aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism. ( Hamasaki, T; Hashimoto, K; Hayashi, RD; Kajimoto, Y; Kitamura, T; Kouhara, H; Kurebayashi, S; Mukai, K; Murata, M; Nakao, M; Otsuki, M; Shimomura, I; Takeiri, S; Tamada, D; Yamamoto, T, 2017)
"To investigate the diagnostic value of plasma aldosterone-to-active-renin ratio(ARR)in combination with plasma aldosterone concentration(PAC)in the predication of aldosteronoma(APA)."	1.43	[An evaluation of plasma aldosterone-to-active-renin ratio in different postures in combination with aldosterone concentration in the diagnosis of aldosteronoma]. ( Ba, JM; Dou, JT; Gu, WJ; Guo, QH; Jin, N; Lyu, ZH; Mu, YM; Wang, XL; Yang, GQ; Yang, LJ; Zang, L; Zhu, J, 2016)
"Little is known about the prevalence of Liddle syndrome."	1.42	Prevalence of Liddle Syndrome Among Young Hypertension Patients of Undetermined Cause in a Chinese Population. ( Bian, J; Hui, RT; Jiang, XJ; Liu, YX; Song, L; Wang, LP; Wu, HY; Yang, KQ; Zhang, HM; Zhou, XL; Zou, YB, 2015)
"Although primary aldosteronism is associated with more prominent cardiac remodeling and diastolic dysfunction, the reversibility of diastolic function is unclear."	1.42	Circulating tissue inhibitor of matrix metalloproteinase-1 is associated with aldosterone-induced diastolic dysfunction. ( Chang, YS; Chang, YY; Chen, MF; Chen, YH; Chou, CH; Ho, YL; Hung, CS; Lin, YH; Su, MJ; Tsai, YC; Wu, KD; Wu, VC; Wu, XM, 2015)
"Aldosterone suppression was assessed in 73 essential hypertensive and 46 primary aldosteronism patients."	1.42	Clinical validation for the aldosterone-to-renin ratio and aldosterone suppression testing using simultaneous fully automated chemiluminescence immunoassays. ( Bidlingmaier, M; Diederich, S; Dietz, A; Fischer, E; Grimminger, P; Holmes, D; Junnila, R; Manolopoulou, J; Morganti, A; Reincke, M, 2015)
"Aldosterone has hypertrophic and profibrotic effects on the heart."	1.42	Plasma aldosterone and left ventricular diastolic function in treatment-naïve patients with hypertension: tissue-Doppler imaging study. ( Catena, C; Kraigher-Krainer, E; Pieske, B; Pilz, S; Sechi, LA; Tomaschitz, A; Verheyen, N, 2015)
"Primary aldosteronism and particularly its most caricatural form, that is APA, seems associated with a lower level of prorenin than essential hypertension."	1.42	Decreased plasma prorenin levels in primary aldosteronism: potential diagnostic implications. ( Berge, C; Bricca, G; Courand, PY; Fauvel, JP; Harbaoui, B; Khettab, F; Lantelme, P; Paget, V, 2015)
"Primary aldosteronism (PA), the most frequent form of secondary hypertension, is characterized by a higher rate of cardiovascular (CV) events than essential hypertension (EH)."	1.40	Primary aldosteronism and essential hypertension: assessment of cardiovascular risk at diagnosis and after treatment. ( Boscaro, M; Ceccoli, L; di Tizio, V; Giacchetti, G; Ronconi, V; Turchi, F, 2014)
"Patients with primary aldosteronism showed significant increase of NADPH oxidase (Nox2-dp) plasma levels and urinary isoprostanes (34."	1.40	Oxidative stress in patients affected by primary aldosteronism. ( Carnevale, R; Concistrè, A; De Toma, G; Letizia, C; Marinelli, C; Petramala, L; Pignatelli, P; Settevendemmie, A; Tonnarini, G; Violi, F; Zinnamosca, L, 2014)
"In 10 patients with primary aldosteronism, median supine ARRP was 298 (range 48-1222) and ARRD 34 (range 2."	1.40	Measurement of plasma renin concentration instead of plasma renin activity decreases the positive aldosterone-to-renin ratio tests in treated patients with essential hypertension. ( Bassani, N; Biganzoli, E; Gritti, A; Lonati, C; Morganti, A, 2014)

Research

Studies (96)

Authors

Clinical Trials (8)

Trial Overview

Trial Outcomes

Apparent Terminal Half-life (T1/2) of LCI699

Timeframe	Studies, this research(%)	All Research%
pre-1990	17 (17.71)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	55 (57.29)	24.3611
2020's	24 (25.00)	2.80

Authors	Studies
Morris, DJ	1
Brem, AS	1
Odermatt, A	1
Petramala, L	3
Concistrè, A	3
Circosta, F	1
Gigante, A	1
Sarlo, F	1
Schina, M	1
Soldini, M	1
Iannucci, G	2
Cianci, R	1
Letizia, C	3
McNally, RJ	1
Morselli, F	1
Farukh, B	1
Chowienczyk, PJ	1
Faconti, L	1
Chen, PT	2
Chang, D	1
Liu, KL	2
Liao, WC	1
Wang, W	2
Chang, CC	5
Wu, VC	10
Lin, YH	11
Chang, CM	1
Peng, KY	2
Chan, CK	2
Lin, YF	1
Liao, HW	1
Chang, JG	1
Wu, MS	1
Chang, WC	1
Han, L	1
Xu, XJ	1
Zhang, JS	1
Liu, HM	1
Hu, YH	2
Lai, TS	1
Wang, SM	2
Lu, CC	1
Liu, YC	1
Tsai, YC	3
Chueh, JS	1
Al-Hashedi, EM	1
Zhao, X	1
Mohammed, AA	1
Juvenal, H	1
Yu, J	1
Gomez-Sanchez, CE	1
Gomez-Sanchez, EP	1
Otsuka, H	2
Abe, M	2
Kobayashi, H	4
Kishimoto, S	2
Oki, K	2
Maruhashi, T	2
Kajikawa, M	2
Mizobuchi, A	1
Harada, T	1
Yamaji, T	1
Hashimoto, Y	1
Yoshimura, K	1
Nakano, Y	1
Goto, C	1
Yusoff, FM	2
Nakashima, A	1
Higashi, Y	3
Li, J	2
Yang, N	1
Chou, H	1
Shi, L	2
Wei, M	1
Li, Y	2
Burrello, J	1
Buffolo, F	1
Domenig, O	1
Tetti, M	1
Pecori, A	1
Monticone, S	1
Poglitsch, M	1
Mulatero, P	1
Libianto, R	1
Fuller, PJ	1
Young, MJ	1
Yang, J	1
Liu, Y	2
Lin, Y	1
Zhang, MM	1
Li, XH	1
Liu, YY	1
Zhao, J	1
Zhang, SL	1
Gao, JW	1
Guo, Y	1
Feng, QL	1
Tang, JY	1
Yan, L	1
Wang, JF	1
Cheng, H	1
Liu, PM	1
Fuss, CT	1
Brohm, K	1
Kurlbaum, M	1
Hannemann, A	1
Kendl, S	1
Fassnacht, M	1
Deutschbein, T	2
Hahner, S	1
Kroiss, M	1
Chu, HT	1
Li, L	1
Jia, M	1
Diao, LL	1
Li, ZB	1
van der Heijden, CDCC	1
Smeets, EMM	1
Aarntzen, EHJG	1
Wesseling, M	1
de Jager, SCA	1
Riksen, NP	1
Teruyama, K	1
Naruse, M	2
Tsuiki, M	1
Pan, CT	2
Wu, XM	4
Tsai, CH	1
Chang, YY	5
Chen, ZW	3
Lee, BC	2
Liao, CW	4
Chen, YL	1
Lin, LC	2
Chang, YR	1
Hung, CS	6
Gideon, A	1
Sauter, C	1
Ehlert, U	1
von Känel, R	1
Wirtz, PH	1
Chen, KM	1
Lin, KH	1
Wu, TH	1
Hong, JS	1
Moon, SJ	1
Jang, HN	1
Kim, JH	1
Moon, MK	1
Ruilope, LM	1
Tamargo, J	1
Spannella, F	1
Giulietti, F	1
Balietti, P	1
Borioni, E	1
Lombardi, FE	1
Ricci, M	1
Cocci, G	1
Landi, L	1
Sarzani, R	1
Haase, M	1
Dringenberg, T	1
Allelein, S	1
Willenberg, HS	1
Schott, M	1
Huang, KC	1
Lee, JK	2
Chen, CW	2
Wu, C	1
Zhang, H	2
Zhang, J	2
Xie, C	1
Fan, C	1
Wu, P	1
Wei, Q	1
Tan, W	1
Xu, L	1
Wang, L	1
Xue, Y	1
Guan, M	1
Song, Y	2
Yang, S	2
He, W	2
Hu, J	2
Cheng, Q	2
Wang, Y	1
Luo, T	1
Ma, L	1
Zhen, Q	2
Zhang, S	1
Mei, M	1
Wang, Z	2
Qing, H	1
Bruemmer, D	1
Peng, B	1
Li, Q	2
Meng, X	1
Wang, X	1
Yu, Y	1
Chou, CH	2
Wei, LH	1
Shun, CT	1
Wen, WF	1
Wan, CH	1
Wu, KD	4
Baron, S	1
Amar, L	1
Faucon, AL	1
Blanchard, A	1
Baffalie, L	1
Faucard, C	1
Travers, S	1
Pagny, JY	1
Azizi, M	1
Houillier, P	1
Davogustto, G	1
Wang, TJ	1
Gupta, DK	1
Ohno, Y	1
Sone, M	1
Inagaki, N	1
Yamasaki, T	1
Ogawa, O	1
Takeda, Y	1
Kurihara, I	1
Umakoshi, H	1
Ichijo, T	1
Katabami, T	1
Wada, N	2
Ogawa, Y	1
Yoshimoto, T	1
Kawashima, J	1
Watanabe, M	1
Matsuda, Y	1
Shibata, H	1
Miyauchi, S	1
Kamemura, K	1
Fukuoka, T	1
Yamamoto, K	1
Otsuki, M	2
Suzuki, T	1
Matsumoto, T	1
Matsui, S	1
Hashimoto, H	1
Kihara, Y	2
Lenzini, L	1
Prisco, S	1
Vanderriele, PE	1
Lerco, S	1
Torresan, F	1
Maiolino, G	1
Seccia, TM	1
Iacobone, M	1
Rossi, GP	1
Bisogni, V	1
Mezzadri, M	1
Olmati, F	1
Saracino, V	1
Oliviero, G	1
Bonvicini, M	1
Tonnarini, G	2
Sung, SH	1
Chen, CH	1
Cheng, HM	1
McQuarrie, EP	1
Freel, EM	1
Mark, PB	1
Fraser, R	1
Connell, JM	1
Jardine, AG	1
Tzamou, V	1
Vyssoulis, G	1
Karpanou, E	1
Kyvelou, SM	1
Gialernios, T	1
Stefanadis, C	1
Chen, AH	1
Li, HY	1
Huang, TS	1
Ceccoli, L	2
Ronconi, V	2
Giovannini, L	1
Marcheggiani, M	1
Turchi, F	2
Boscaro, M	2
Giacchetti, G	2
Wu, CH	1
Yang, YW	1
Kuo, KL	1
Hung, SC	1
Jin, S	1
Takahashi, Y	1
Hui, SP	1
Sakurai, T	1
Fuda, H	1
Takeda, S	1
Fujikawa, M	1
Yanagisawa, K	1
Ikegawa, S	1
Kurosawa, T	1
Chiba, H	1
Schumacher, CD	1
Steele, RE	1
Brunner, HR	1
He, YB	1
Yu, X	1
Zhou, XR	1
Shu, BH	1
Liu, JH	1
Lonati, C	1
Bassani, N	1
Gritti, A	1
Biganzoli, E	1
Morganti, A	2
Liu, YZ	1
Wu, JJ	1
Zhang, L	1
Xu, H	1
Liu, Z	1
Lu, JP	1
Feng, L	1
Guo, Q	1
Zhao, CM	1
Liu, JX	1
Wei, H	1
Cao, S	1
Zhao, H	1
Pilz, S	3
Kienreich, K	1
Gaksch, M	2
Grübler, M	1
Verheyen, N	3
Bersuch, LA	1
Schmid, J	1
Drechsler, C	1
Ritz, E	2
Moosbrugger, A	1
Stepan, V	1
Pieber, TR	1
Meinitzer, A	2
März, W	2
Tomaschitz, A	3
di Tizio, V	1
Piecha, G	1
Haas, J	1
Pieske, B	2
Wiecek, A	1
Rus-Machan, J	1
Toplak, H	1
Amrein, K	1
Kraigher-Krainer, E	2
Fahrleitner-Pammer, A	1
Lee, HH	1
Liao, MT	1
Chen, YH	2
Pignatelli, P	1
Carnevale, R	1
Zinnamosca, L	1
Marinelli, C	1
Settevendemmie, A	1
De Toma, G	1
Violi, F	1
Berge, C	1
Courand, PY	1
Harbaoui, B	1
Paget, V	1
Khettab, F	1
Bricca, G	1
Fauvel, JP	1
Lantelme, P	1
Chittani, M	1
Zaninello, R	1
Lanzani, C	2
Frau, F	1
Ortu, MF	1
Salvi, E	1
Fresu, G	1
Citterio, L	1
Braga, D	1
Piras, DA	1
Carpini, SD	1
Velayutham, D	1
Simonini, M	2
Argiolas, G	1
Pozzoli, S	1
Troffa, C	1
Glorioso, V	1
Kontula, KK	1
Hiltunen, TP	1
Donner, KM	1
Turner, ST	1
Boerwinkle, E	1
Chapman, AB	1
Padmanabhan, S	1
Dominiczak, AF	1
Melander, O	1
Johnson, JA	1
Cooper-Dehoff, RM	1
Gong, Y	1
Rivera, NV	1
Condorelli, G	1
Trimarco, B	1
Manunta, P	2
Cusi, D	1
Glorioso, N	1
Barlassina, C	1
Catena, C	2
Sechi, LA	2
Markou, A	1
Sertedaki, A	1
Kaltsas, G	1
Androulakis, II	1
Marakaki, C	1
Pappa, T	1
Gouli, A	1
Papanastasiou, L	1
Fountoulakis, S	1
Zacharoulis, A	1
Karavidas, A	1
Ragkou, D	1
Charmandari, E	1
Chrousos, GP	1
Piaditis, GP	1
Titov, VN	1
Cho, JS	1
Ihm, SH	1
Kim, CJ	1
Park, MW	1
Her, SH	1
Park, GM	1
Kim, TS	1
Wang, LP	1
Yang, KQ	1
Jiang, XJ	1
Wu, HY	1
Zhang, HM	1
Zou, YB	1
Song, L	1
Bian, J	1
Hui, RT	1
Liu, YX	1
Zhou, XL	1
Chang, YS	1
Su, MJ	1
Ho, YL	1
Chen, MF	1
Manolopoulou, J	1
Fischer, E	1
Dietz, A	1
Diederich, S	1
Holmes, D	1
Junnila, R	1
Grimminger, P	1
Reincke, M	1
Bidlingmaier, M	1
Colussi, G	1
Brosolo, G	1
Novello, M	1
Jiang, Y	1
Zhang, C	1
Ye, L	1
Su, T	1
Zhou, W	1
Jiang, L	1
Zhang, Y	1
Long, J	1
Feng, Z	1
Li, R	1
Ren, W	1
Zhou, B	1
Sezai, A	1
Osaka, S	1
Yaoita, H	1
Arimoto, M	1
Hata, H	1
Shiono, M	1
Sakino, H	1
Zhu, J	1
Jin, N	1
Zang, L	1
Gu, WJ	1
Yang, GQ	1
Yang, LJ	1
Guo, QH	1
Wang, XL	1
Lyu, ZH	1
Ba, JM	1
Dou, JT	1
Mu, YM	1
Schütten, MTJ	1
Houben, AJHM	1
Kroon, AA	1
Stehouwer, CDA	1
de Leeuw, PW	1
Tentori, S	1
Messaggio, E	1
Brioni, E	1
Casamassima, N	1
Zagato, L	1
Hamlyn, JM	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
LC-MS/MS-specific Cutoffs for Screening and Confirmatory Testing of Primary Aldosteronism: A Multi-center Study[NCT05959863]		300 participants (Anticipated)	Observational	2023-08-30	Recruiting
A Phase II, Randomized, Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Effects of LCI699 on Cortisol in Patients With Hypertension[NCT00817414]	Phase 2	63 participants (Actual)	Interventional	2009-01-14	Completed
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Finding Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo After 8 Weeks Treatment in Patients With Essential Hypertension[NCT00758524]	Phase 2	628 participants (Actual)	Interventional	2008-09-11	Completed
A Phase II, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Multi-center, Dose Ranging Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo After 8 Weeks Treatment in Patients With Resistant Hypertension[NCT00817635]	Phase 2	155 participants (Actual)	Interventional	2008-12-22	Completed
A Pilot, Single-blind, Forced-titration Study to Assess the Hemodynamic and Hormonal Effects, Safety and Tolerability of the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism[NCT00732771]	Phase 2	12 participants (Anticipated)	Interventional	2008-06-30	Completed
Increasing Stay-on-therapy in Hypertensive Patients Treated With First-line Diuretics: An Active Pharmacosurveillance and Pharmacogenetic Study.[NCT00408512]	Phase 4	2,500 participants (Anticipated)	Interventional	2006-12-31	Completed
Hypertension in High School Students: Genetic and Environmental Factors[NCT06049641]		2,638 participants (Actual)	Observational	2014-10-31	Completed
Technology Assisted Management of Uncontrolled Hypertension (TEAM-HTN): a Pilot Study[NCT03281772]		180 participants (Anticipated)	Observational	2017-01-24	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

(NCT00817414)
Timeframe: Days 7, 28: Pre-dose and 3 hours post-dose; Day 30: Pre-dose; Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose

Area Under the Concentration Time Curve From Time 0 to 8 Hours Post LCI699 Administration (AUC0-8)

Intervention	hr (Geometric Mean)
Cohort A: LCI699 0.5 mg QD	4.67
Cohort A: LCI699 1.0 mg QD	3.79
Cohort B1: LCI699 1.0 mg BID	5.52
Cohort B1: LCI699 2.0 mg QD	4.90

(NCT00817414)
Timeframe: Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose

Area Under the Concentration Time Curve Over the Dosing Interval (AUC0-τ) for LCI699

Intervention	nanogramhour per milliliter (nghr/mL) (Geometric Mean)
Cohort A: LCI699 0.5 mg QD	6.60
Cohort A: LCI699 1.0 mg QD	14.1
Cohort B1: LCI699 1.0 mg BID	24.1
Cohort B1: LCI699 2.0 mg QD	46.4

(NCT00817414)
Timeframe: Days 7, 28: Pre-dose and 3 hours post-dose; Day 30: Pre-dose; Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose

LCI699 Plasma Concentration Post LCI699 Administration at Day 7

Maximum Plasma Concentration (Cmax) of LCI699

Intervention	ng*hr/mL (Geometric Mean)
Cohort A: LCI699 0.5 mg QD	9.23
Cohort A: LCI699 1.0 mg QD	18.8
Cohort B1: LCI699 1.0 mg BID	30.6
Cohort B1: LCI699 2.0 mg QD	68.9

Intervention	nanogram per milliliter (ng/mL) (Geometric Mean)
Cohort A: LCI699 0.5 mg QD	1.51
Cohort A: LCI699 1.0 mg QD	2.88
Cohort B1: LCI699 1.0 mg BID	3.92
Cohort B1: LCI699 2.0 mg QD	6.73

(NCT00817414)
Timeframe: Days 7, 28: Pre-dose and 3 hours post-dose; Day 30: Pre-dose; Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose

Maximum Tolerated Dose (MTD) of LCI699 With Respect to Effect on the Adrenocorticotropic Hormone (ACTH)-Stimulated Cortisol Response Following ACTH Stimulation in Hypertensive Participants

Intervention	ng/mL (Geometric Mean)
Cohort A: LCI699 0.5 mg QD	1.42
Cohort A: LCI699 1.0 mg QD	2.94
Cohort B1: LCI699 1.0 mg BID	4.62
Cohort B1: LCI699 2.0 mg QD	8.86

As per the protocol, MTD is the dose at which 4 participants exhibited ACTH-stimulated cortisol results <400 nanomoles per liter (nmol/L). The change in the distribution across the treatments were analyzed using 1- way analysis of variance (ANOVA) for continuous variables. (NCT00817414)
Timeframe: Up to Week 6

Number of Participants With Adverse Event (AEs)

Intervention	milligrams (mg) (Number)
LCI699	1.30

An AE is an adverse medical event which occurs in a participant of the study and which is not necessarily in a causal relationship with the treatment the participant receives. (NCT00817414)
Timeframe: Up to 8 weeks

Time of Maximum Plasma Concentration (Tmax) of LCI699

Intervention	Participants (Count of Participants)
Cohort A: LCI699 0.5 mg QD	6
Cohort A: LCI699 1 mg QD	9
Cohort B1: LCI699 1 mg BID	10
Cohort B1: LCI699 2 mg QD	10
Placebo	10

(NCT00817414)
Timeframe: Days 7, 28: Pre-dose and 3 hours post-dose; Day 30: Pre-dose; Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose

LCI699 Exposure-response Relationship on Cortisol Levels Following ACTH Stimulation in Hypertensive Participants

Intervention	hour (hr) (Median)
Cohort A: LCI699 0.5 mg QD	2.21
Cohort A: LCI699 1.0 mg QD	1.00
Cohort B1: LCI699 1.0 mg BID	1.00
Cohort B1: LCI699 2.0 mg QD	1.00

Exposure-response relationship was assessed using ACTH stimulation test. Tests were done 2 hours after study drug administration (i.e., at peak LCI699 concentrations). An increase in cortisol greater than >500 nmol at 60 minutes after ACTH administration was expected. (NCT00817414)
Timeframe: Up to Week 6

Percentage of Participants With a Mean Sitting Diastolic Blood Pressure (MSDBP) Response and MSDBP Control at Week 6 LOCF, as Measured by OBP

Intervention	nanomoles per liter (nmol/L) (Mean)
	Day 7	Day 28	Day 42
Cohort A: LCI699 0.5 mg QD	690.0	634.87	647.51
Cohort A: LCI699 1.0 mg QD	669.40	573.41	626.08
Cohort B1: LCI699 1.0 mg BID	625.06	554.79	539.68
Cohort B1: LCI699 2.0 mg QD	562.04	539.09	479.91
Placebo	799.06	804.86	812.91

Automated arterial BP determinations was made with an automated BP device (such as the Omron BP monitor) in accordance with the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV. Sitting and standing BP and HR measurements were performed. MSDBP response was defined as the percentage of participants with a MSDBP <90 mmHg or a >= 10 mmHg reduction from baseline. MSDBP control was defined as the percentage of participants with a MSDBP <90 mmHg for non-diabetic participants and <80mHg for diabetic participants. (NCT00817414)
Timeframe: Week 6

Percentage of Participants With a Mean Sitting Systolic Blood Pressure (MSSBP) Response and MSSBP Control at Week 6 Last Observation Carried Forward (LOCF), as Measured by Office Blood Pressure (OBP)

Intervention	percentage of participants (Number)
	MSDBP Response	MSDBP Control
Cohort A: LCI699 0.5 mg QD	58.3	58.3
Cohort A: LCI699 1 mg QD	66.7	66.7
Cohort B1: LCI699 1 mg BID	100	76.9
Cohort B1: LCI699 2 mg QD	76.9	76.9
Placebo	61.5	46.2

Automated arterial BP determinations was made with an automated BP device (such as the Omron BP monitor) in accordance with the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV. Sitting and standing blood pressure (BP) and heart rate (HR) measurements were performed. MSSBP response was defined as the percentage of participants with a MSSBP <140 mmHg or a >=20 mmHg reduction from baseline. MSSBP control was defined as the percentage of participants with a MSSBP <140 mmHg for non-diabetic participants and <130mHg for diabetic participants. (NCT00817414)
Timeframe: Week 6

Core Period: Change From Baseline in Mean 24 Hour Ambulatory DBP at Week 8, as Measured by ABPM

Intervention	percentage of participants (Number)
	MSSBP Response	MSSBP Control
Cohort A: LCI699 0.5 mg QD	58.3	50.0
Cohort A: LCI699 1 mg QD	50.0	41.7
Cohort B1: LCI699 1 mg BID	69.2	61.5
Cohort B1: LCI699 2 mg QD	76.9	76.9
Placebo	61.5	53.8

An ABPM measured a participant's BP over a 24-hour period readings using an automated validated monitoring device from Baseline to Week 8. The 24-hour DBP was calculated by taking the mean of all ambulatory DBP readings for the 24-hour period. (NCT00758524)
Timeframe: Baseline, Week 8

Core Period: Change From Baseline in Mean 24 Hour Ambulatory SBP at Week 8 as Measured by Ambulatory Blood Pressure Monitoring (ABPM)

Intervention	mm Hg (Least Squares Mean)
Core Period: LCI699 0.25 mg QD	-4.03
Core Period: LCI699 0.5 mg QD	-2.44
Core Period: LCI699 1.0 mg QD	-4.96
Core Period: LCI699 0.5 mg BID	-2.75
Core Period: Eplerenone 50 mg BID	-6.03
Core Period: Placebo	1.03

An ABPM measured a participant's BP over a 24-hour period readings using an automated validated monitoring device from Baseline to Week 8. The 24-hour SBP was calculated by taking the mean of all ambulatory SBP readings for the 24-hour period. (NCT00758524)
Timeframe: Baseline, Week 8

Core Period: Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8 Last Observation Carried Forward (LOCF), as Measured by Office Blood Pressure (OBP)

Intervention	mm Hg (Least Squares Mean)
Core Period: LCI699 0.25 mg QD	-7.15
Core Period: LCI699 0.5 mg QD	-4.90
Core Period: LCI699 1.0 mg QD	-7.73
Core Period: LCI699 0.5 mg BID	-6.18
Core Period: Eplerenone 50 mg BID	-10.52
Core Period: Placebo	1.11

Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSDBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and region as factors and baseline MSDBP level as a covariate. (NCT00758524)
Timeframe: Baseline, Week 8

Core Period: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8 LOCF, as Measured by OBP

Intervention	mm Hg (Mean)
Core Period: LCI699 0.25 mg QD	-4.47
Core Period: LCI699 0.5 mg QD	-5.50
Core Period: LCI699 1.0 mg QD	-7.11
Core Period: LCI699 0.5 mg BID	-4.25
Core Period: Eplerenone 50 mg BID	-7.49
Core Period: Placebo	-3.22

Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSSBP was analyzed using an ANCOVA with treatment and region as factors and baseline MSSBP levels as a covariate. (NCT00758524)
Timeframe: Baseline, Week 8

Core Period: Change From Baseline in Plasma Aldosterone Levels at Week 8

Intervention	mm Hg (Mean)
Core Period: LCI699 0.25 mg QD	-9.00
Core Period: LCI699 0.5 mg QD	-10.69
Core Period: LCI699 1.0 mg QD	-11.93
Core Period: LCI699 0.5 mg BID	-9.10
Core Period: Eplerenone 50 mg BID	-13.31
Core Period: Placebo	-2.93

Change from baseline was analyzed using plasma aldosterone values measured at Baseline and Week 8. (NCT00758524)
Timeframe: Baseline, Week 8

Core Period: Change From Baseline in Plasma Cortisol Levels by Adrenocorticotropic Hormone (ACTH) Stimulation Test

Intervention	picomoles per liter (pmol/L) (Mean)
Core Period: LCI699 0.25 mg QD	-21.5
Core Period: LCI699 0.5 mg QD	-20.0
Core Period: LCI699 1.0 mg QD	-9.9
Core Period: LCI699 0.5 mg BID	-47.5
Core Period: Eplerenone 50 mg BID	277.1
Core Period: Placebo	-28.8

The ACTH stimulation cortisol test was a standard procedure to measure the ability of adrenal cortex to respond to exogenous ACTH and directly assess the adrenal reserve. Serum cortisol concentrations at 1 hour after injection were measured to assess the maximum stimulated cortisol level achieved. Potential adrenal suppression was indicated if the serum cortisol concentration was <500 nanomoles per liter (nmol/L) at 1 hour after the injection. (NCT00758524)
Timeframe: Baseline, 1 hour post-dose at Week 8

Core Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSDBP at Week 8

Intervention	nanomoles per liter (nmol/L) (Mean)
Core Period: LCI699 0.25 mg QD	729.20
Core Period: LCI699 0.5 mg QD	692.74
Core Period: LCI699 1.0 mg QD	604.46
Core Period: LCI699 0.5 mg BID	609.21
Core Period: Eplerenone 50 mg BID	802.32
Core Period: Placebo	822.65

Core Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSSBP at Week 8

Intervention	mm Hg (Mean)
Core Period: LCI699 0.25 mg QD	-4.47
Core Period: LCI699 0.5 mg QD	-5.50
Core Period: LCI699 1.0 mg QD	-7.11
Core Period: LCI699 0.5 mg BID	-4.25

Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSSBP was analyzed using an ANCOVA with treatment and region as factors and baseline MSSBP levels as a covariate. (NCT00758524)
Timeframe: Baseline, Week 8

Withdrawal Period: Change From Week 8 to Week 9 in MSDBP at Week 9, as Measured by OBP

Intervention	mm Hg (Mean)
Core Period: LCI699 0.25 mg QD	-9.00
Core Period: LCI699 0.5 mg QD	-10.69
Core Period: LCI699 1.0 mg QD	-11.93
Core Period: LCI699 0.5 mg BID	-9.10

Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 9 readings to the readings taken at Week 8 (Baseline). The change from Week 8 to week 9 in MSDBP was analyzed using an ANCOVA with treatment and region as factors and Week 8 MSDBP level as a covariate. (NCT00758524)
Timeframe: From Week 8 to Week 9

Withdrawal Period: Change From Week 8 to Week 9 in MSSBP at Week 9 as Measured by OBP

Intervention	mm Hg (Least Squares Mean)
Withdrawal Period: LCI699 0.25 mg QD	0.5
Withdrawal Period: LCI699 0.25 mg QD Placebo	0.5
Withdrawal Period: LCI699 0.5 mg QD	1.6
Withdrawal Period: LCI699 0.5 mg QD Placebo	-0.2
Withdrawal Period: LCI699 1.0 mg QD	-0.5
Withdrawal Period: LCI699 1.0 mg QD Placebo	2.5
Withdrawal Period: LCI699 0.5 mg BID	1.3
Withdrawal Period: LCI699 0.5 mg BID Placebo	1.3
Withdrawal Period: Eplerenone 50 mg BID	-1.2
Withdrawal Period: Eplerenone 50 mg BID Placebo	0.4
Withdrawal Period: Placebo	1.6

Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 9 readings to the readings taken at Week 8 (Baseline). The change from Week 8 to week 9 in MSSBP was analyzed using an ANCOVA with treatment and region as factors and Week 8 MSSBP level as a covariate. (NCT00758524)
Timeframe: From Week 8 to Week 9

Core Period: Number of Participants With Adverse Event (AEs), Serious Adverse Events (SAEs), and Deaths

Intervention	mm Hg (Least Squares Mean)
Withdrawal Period: LCI699 0.25 mg QD	0.3
Withdrawal Period: LCI699 0.25 mg QD Placebo	3.3
Withdrawal Period: LCI699 0.5 mg QD	0.5
Withdrawal Period: LCI699 0.5 mg QD Placebo	2.5
Withdrawal Period: LCI699 1.0 mg QD	0.4
Withdrawal Period: LCI699 1.0 mg QD Placebo	5.3
Withdrawal Period: LCI699 0.5 mg BID	1.6
Withdrawal Period: LCI699 0.5 mg BID Placebo	4.4
Withdrawal Period: Eplerenone 50 mg BID	-1.5
Withdrawal Period: Eplerenone 50 mg BID Placebo	2.7
Withdrawal Period: Placebo	1.8

Core Period: Percentage of Participants With a MSDBP Response and MSDBP Control at Week 8 LOCF

Intervention	Participants (Count of Participants)
	AEs	SAEs	Deaths
Core Period: Eplerenone 50 mg BID	26	0	0
Core Period: LCI699 0.25 mg QD	23	1	0
Core Period: LCI699 0.5 mg BID	27	0	0
Core Period: LCI699 0.5 mg QD	22	0	0
Core Period: LCI699 1.0 mg QD	24	0	0
Core Period: Placebo	23	1	0

MSDBP response was defined as the percentage of participants with a MSDBP <90 mmHg or a >=10 mmHg reduction from Baseline. MSDBP control was defined as the percentage of participants with a MSDBP <90 mmHg. (NCT00758524)
Timeframe: Baseline, Week 8

Core Period: Percentage of Participants With a MSSBP Response and MSSBP Control at Week 8 LOCF

Intervention	percentage of participants (Number)
	MSDBP Response	MSDBP Control
Core Period: Eplerenone 50 mg BID	48.8	45.2
Core Period: LCI699 0.25 mg QD	39.1	32.6
Core Period: LCI699 0.5 mg BID	34.4	29.2
Core Period: LCI699 0.5 mg QD	34.1	29.4
Core Period: LCI699 1.0 mg QD	50.0	41.9
Core Period: Placebo	27.6	18.4

MSSBP response was defined as the percentage of participants with a MSSBP <140 mmHg or a >=20 mmHg reduction from baseline reduction from baseline. MSSBP control was defined as the percentage of participants with a MSSBP <140 mmHg. (NCT00758524)
Timeframe: Baseline, Week 8

Core Period: Trough to Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory DBP at Week 8

Intervention	percentage of participants (Number)
	MSSBP Response	MSSBP Control
Core Period: Eplerenone 50 mg BID	52.4	44.0
Core Period: LCI699 0.25 mg QD	39.1	31.5
Core Period: LCI699 0.5 mg BID	34.4	25.0
Core Period: LCI699 0.5 mg QD	37.6	27.1
Core Period: LCI699 1.0 mg QD	48.8	40.7
Core Period: Placebo	17.1	15.8

Trough to peak ratios were derived from an ANCOVA model containing treatment, region, hour, treatment by hour interaction as factors with Baseline as a covariate. (NCT00758524)
Timeframe: Baseline, every hour up to 24 hours post-dose at Week 8

Core Period: Trough to Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory SBP at Week 8

Intervention	ratio (Least Squares Mean)
	Week 8, Hour 1	Week 8, Hour 2	Week 8, Hour 3	Week 8, Hour 4	Week 8, Hour 5	Week 8, Hour 6	Week 8, Hour 7	Week 8, Hour 8	Week 8, Hour 9	Week 8, Hour 10	Week 8, Hour 11	Week 8, Hour 12	Week 8, Hour 13	Week 8, Hour 14	Week 8, Hour 15	Week 8, Hour 16	Week 8, Hour 17	Week 8, Hour 18	Week 8, Hour 19	Week 8, Hour 20	Week 8, Hour 21	Week 8, Hour 22	Week 8, Hour 23	Week 8, Hour 24
Core Period: Eplerenone 50 mg BID	0.17	-1.65	-2.42	-1.39	-2.91	-4.86	-3.70	-2.30	-2.81	-2.43	-1.93	-3.20	-5.35	-7.64	-9.03	-12.55	-12.88	-13.49	-10.13	-10.47	-10.51	-7.60	-5.54	-2.78
Core Period: LCI699 0.25 mg QD	3.91	1.44	1.16	0.51	1.11	-1.18	-1.85	-3.01	-1.24	-0.59	-1.02	-1.60	-4.32	-6.47	-8.34	-8.92	-10.26	-10.68	-10.13	-10.73	-9.31	-7.90	-4.94	-0.21
Core Period: LCI699 0.5 mg BID	3.87	3.44	4.01	2.64	1.45	1.20	1.21	2.09	3.27	0.49	1.54	-1.06	-1.45	-2.96	-6.10	-9.54	-10.38	-11.85	-10.78	-10.49	-8.22	-6.35	-2.67	1.36
Core Period: LCI699 0.5 mg QD	2.95	1.85	1.13	2.91	-0.02	-2.36	-0.95	-1.38	-0.07	2.60	1.72	2.53	-1.20	-3.29	-5.82	-8.37	-10.99	-11.73	-10.12	-8.06	-7.68	-4.93	-1.93	1.45
Core Period: LCI699 1.0 mg QD	0.27	0.17	-0.36	0.35	-1.69	-3.01	-2.63	-2.43	-2.25	-1.65	-1.54	-3.10	-5.31	-7.38	-8.89	-10.50	-12.71	-11.88	-9.74	-10.43	-9.66	-5.37	-1.18	0.29
Core Period: Placebo	7.11	6.28	4.99	7.02	4.31	1.82	3.62	2.65	3.30	3.86	2.38	3.24	1.52	-0.90	-1.01	-1.61	-4.20	-6.89	-5.84	-5.21	-4.12	-1.09	1.82	1.98

Change From Baseline in MSDBP at Week 8 LOCF

Intervention	ratio (Least Squares Mean)
	Week 8, Hour 1	Week 8, Hour 2	Week 8, Hour 3	Week 8, Hour 4	Week 8, Hour 5	Week 8, Hour 6	Week 8, Hour 7	Week 8, Hour 8	Week 8, Hour 9	Week 8, Hour 10	Week 8, Hour 11	Week 8, Hour 12	Week 8, Hour 13	Week 8, Hour 14	Week 8, Hour 15	Week 8, Hour 16	Week 8, Hour 17	Week 8, Hour 18	Week 8, Hour 19	Week 8, Hour 20	Week 8, Hour 21	Week 8, Hour 22	Week 8, Hour 23	Week 8, Hour 24
Core Period: Eplerenone 50 mg BID	-5.33	-5.90	-5.89	-5.12	-7.22	-7.91	-8.70	-8.06	-7.46	-7.35	-5.75	-6.25	-8.81	-10.91	-12.04	-16.68	-19.59	-18.55	-15.49	-16.09	-15.34	-12.47	-9.02	-8.90
Core Period: LCI699 0.25 mg QD	-0.54	-1.59	-2.11	-2.06	-4.29	-4.21	-4.95	-5.28	-3.98	-3.69	-2.47	-5.19	-6.45	-7.37	-10.61	-11.71	-13.71	-14.49	-13.78	-13.92	-14.33	-13.46	-7.88	-3.16
Core Period: LCI699 0.5 mg BID	-1.42	-0.57	0.91	1.50	-1.70	-1.02	-0.76	-3.02	-1.87	-1.73	-1.74	-3.92	-4.05	-6.12	-9.78	-13.03	-13.72	-15.60	-15.93	-15.47	-13.63	-10.55	-6.73	-3.76
Core Period: LCI699 0.5 mg QD	0.09	0.15	-1.53	-1.18	-3.09	-3.12	-2.10	-4.69	-1.59	-0.30	-0.43	0.73	-2.30	-5.68	-8.28	-10.01	-11.96	-14.37	-13.08	-13.22	-10.06	-8.35	-6.23	-0.64
Core Period: LCI699 1.0 mg QD	-4.51	-3.56	-4.86	-4.15	-3.47	-5.88	-5.40	-5.30	-4.78	-3.40	-4.22	-4.35	-7.25	-9.33	-11.26	-12.63	-15.46	-14.54	-12.85	-12.54	-12.78	-7.52	-5.77	-3.45
Core Period: Placebo	8.23	6.48	4.60	4.68	2.78	1.42	2.25	3.76	2.39	2.54	3.51	4.69	3.20	0.75	0.02	-0.33	-3.03	-6.35	-6.98	-6.53	-3.89	-0.94	2.18	0.70

Arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from Baseline in MSDBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate. (NCT00817635)
Timeframe: Baseline, Week 8

Change From Baseline in MSSBP at Week 8 Last Observation Carried Forward (LOCF)

Intervention	mmHg (Mean)
LCI699 0.25 mg BID	-4.5
LCI699 1 mg QD	-6.0
LCI699 0.5 mg Followed by LCI699 1 mg BID	-6.1
Eplerenone 50 mg BID	-7.7
Placebo	-4.8

Arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from Baseline in MSSBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and country as factors and Baseline MSSBP as a covariate. (NCT00817635)
Timeframe: Baseline, Week 8

Dose/Exposure BP Response Relationship of LCI699, as Measured by Change From Baseline in MSDBP at Week 8

Intervention	mmHg (Mean)
LCI699 0.25 mg BID	-11.4
LCI699 1 mg QD	-13.1
LCI699 0.5 mg Followed by LCI699 1 mg BID	-12.5
Eplerenone 50 mg BID	-18.7
Placebo	-8.8

Dose/Exposure BP Response Relationship of LCI699, as Measured by Change From Baseline in MSSBP at Week 8

Intervention	mmHg (Mean)
LCI699 0.25 mg BID	-4.5
LCI699 1 mg QD	-6.0
LCI699 0.5 mg Followed by LCI699 1 mg BID	-6.1

Arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from Baseline in MSSBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSSBP as a covariate. (NCT00817635)
Timeframe: Baseline, Week 8

Number of Participants With Cortisol Levels Below 500 Nmol/L at 1 Hour After Adrenocorticotropic Hormone (ACTH) Injection at Week 8

Intervention	mmHg (Mean)
LCI699 0.25 mg BID	-11.4
LCI699 1 mg QD	-13.1
LCI699 0.5 mg Followed by LCI699 1 mg BID	-12.5

Serum cortisol concentrations at 1 hour after injection were measured to assess the maximum stimulated cortisol level achieved. Potential adrenal suppression was indicated if the serum cortisol concentration was <500 nanomoles per liter (nmol/L) at 1 hour after the injection. (NCT00817635)
Timeframe: 1-hour post-dose at Week 8

Percent Change From Baseline in RAAS Biomarker: Active Renin (ARC) in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF

Intervention	Participants (Count of Participants)
LCI699 0.25 mg BID	0
LCI699 1 mg QD	1
LCI699 0.5 mg Followed by LCI699 1 mg BID	4
Eplerenone 50 mg BID	0
Placebo	0

Percent change from Baseline was analyzed by ANCOVA model using active renin values measured at Baseline and Week 8 LOCF, with treatment and country as factors and Baseline value as the covariate. Negative percent change from Baseline shows improvement. (NCT00817635)
Timeframe: Baseline, Week 8

Percent Change From Baseline in RAAS Biomarker: Plasma Renin Activity (PRA) in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF

Intervention	percent change in ARC (Geometric Least Squares Mean)
LCI699 0.25 mg BID	73.1
LCI699 1 mg QD	72.8
LCI699 0.5 mg Followed by LCI699 1 mg BID	156.4
Eplerenone 50 mg BID	430.6

Percent change from Baseline was analyzed by ANCOVA model using plasma renin values measured at Baseline and Week 8 LOCF, with treatment and country as factors and Baseline value as the covariate. Negative percent change from Baseline shows improvement. (NCT00817635)
Timeframe: Baseline, Week 8

Percent Change From Baseline in RAAS Biomarker: Ratio of PA to PRA in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF

Intervention	percent change in PRA (Geometric Least Squares Mean)
LCI699 0.25 mg BID	41.6
LCI699 1 mg QD	74.3
LCI699 0.5 mg Followed by LCI699 1 mg BID	107.7
Eplerenone 50 mg BID	414.1

Percent change from Baseline was analyzed by ANCOVA model using percent ratio of PA to PRA values measured at Baseline and Week 8 LOCF, with treatment and country as factors and Baseline value as the covariate. Negative percent change from Baseline shows improvement. (NCT00817635)
Timeframe: Baseline, Week 8

Percent Change From Baseline in Renin-Angiotensin-Aldosterone-System (RAAS) Biomarker: Plasma Aldosterone (PA) in LCI699 Compared to Eplerenone 50 mg at Week 8 LOCF

Intervention	percent change in ratio of PA to PRA (Geometric Least Squares Mean)
LCI699 0.25 mg BID	-46.7
LCI699 1 mg QD	-50.0
LCI699 0.5 mg Followed by LCI699 1 mg BID	-78.3
Eplerenone 50 mg BID	-57.1

Percent change from Baseline was analyzed by ANCOVA model using PA values measured at Baseline and Week 8 LOCF, with treatment and country as factors and Baseline value as the covariate. Negative percent change from Baseline shows improvement. (NCT00817635)
Timeframe: Baseline, Week 8

Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime DBP in LCI699 1mg QD Versus LCI699 0.5mg BID Arm at Week 4, as Measured by ABPM

Intervention	percent change in aldosterone (Geometric Least Squares Mean)
LCI699 0.25 mg BID	-22.3
LCI699 1 mg QD	-30.4
LCI699 0.5 mg Followed by LCI699 1 mg BID	-53.1
Eplerenone 50 mg BID	115.0

An ABPM measured a participant's blood pressure over a 24-hour period including daytime and nighttime readings using an automated validated monitoring device from Baseline to Week 4. The 24-hour DBP was calculated by taking the mean of all ambulatory diastolic blood pressure readings for the 24-hour period. The change from Baseline in DBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate. (NCT00817635)
Timeframe: Baseline, Week 4

Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime Diastolic Blood Pressure (DBP) at Week 8 LOCF, as Measured by ABPM

Intervention	mmHg (Mean)
	24-hour Mean DBP	Daytime Mean DBP	Nighttime Mean DBP
LCI699 0.5 mg BID	-2.5	-2.6	-2.8
LCI699 1 mg QD	-4.3	-3.9	-4.5

An ABPM measured a participant's blood pressure over a 24-hour period including daytime and nighttime readings, using an automated validated monitoring device from Baseline to Week 8. The 24-hour DBP was calculated by taking the mean of all ambulatory diastolic blood pressure readings for the 24-hour period. The change from Baseline in DBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate. (NCT00817635)
Timeframe: Baseline, Week 8

Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime SBP in LCI699 1mg QD Versus LCI699 0.5mg BID Arm at Week 4, as Measured by ABPM

Intervention	mmHg (Mean)
	24-hour Mean DBP	Daytime Mean DBP	Nighttime Mean DBP
Eplerenone 50 mg BID	-9.6	-9.5	-9.6
LCI699 0.25 mg BID	1.0	0.6	1.9
LCI699 0.5 mg Followed by LCI699 1 mg BID	-3.7	-3.4	-4.6
LCI699 1 mg QD	-3.4	-3.6	-2.5
Placebo	-0.2	-0.8	1.2

An ABPM measured a participant's blood pressure over a 24-hour period including daytime and nighttime readings using an automated validated monitoring device from Baseline to Week 4. The 24-hour SBP was calculated by taking the mean of all ambulatory systolic blood pressure readings for the 24-hour period. The change from Baseline in SBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate. (NCT00817635)
Timeframe: Baseline, Week 4

Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime Systolic Blood Pressure (SBP) at Week 8 LOCF, as Measured by Ambulatory Blood Pressure Measurement (ABPM)

Intervention	mmHg (Mean)
	24-hour Mean SBP	Daytime Mean SBP	Nighttime Mean SBP
LCI699 0.5 mg BID	-4.7	-5.3	-4.5
LCI699 1 mg QD	-7.8	-8.1	-6.8

An ABPM measured a participant's blood pressure over a 24-hour period including daytime and nighttime readings, using an automated validated monitoring device from Baseline to Week 8. The 24-hour SBP was calculated by taking the mean of all ambulatory systolic blood pressure readings for the 24-hour period. The change from Baseline in SBP was analyzed using ANCOVA with treatment and country as factors and Baseline MSSBP as a covariate. (NCT00817635)
Timeframe: Baseline, Week 8

Number of Participants With Adverse Event (AEs), Serious Adverse Events (SAEs), Hyperkalemia, and Hyponatremia

Intervention	mmHg (Mean)
	24-hour Mean SBP	Daytime Mean SBP	Nighttime Mean SBP
Eplerenone 50 mg BID	-15.7	-15.7	-15.4
LCI699 0.25 mg BID	-4.4	-4.9	-3.2
LCI699 0.5 mg Followed by LCI699 1 mg BID	-6.3	-6.3	-7.0
LCI699 1 mg QD	-5.7	-6.0	-4.8
Placebo	-1.0	-1.6	0.4

An AE was an adverse medical event which occurs in a participant of the study and which is not necessarily in a causal relationship with the treatment the participant receives. SAEs were AEs leading to death, are life-threatening, require hospitalizations or prolongation of hospitalizations, represent an innate malformation or a congenital abnormality. Hyperkalemia was defined as potassium level >5.5 millimoles per liter (mmol/L). It is the medical term that describes a potassium level that's higher than normal. Hyponatremia was defined as sodium level <135 mmol/L. It is the medical term that describes a sodium level that's lesser than normal. (NCT00817635)
Timeframe: AEs, Hyperkalemia, and Hyponatremia: From start of the study drug treatment up to 10 weeks; SAE: From signing of the informed consent up to 10 weeks

Percentage of Participants With a MSDBP Response and MSDBP Control at Week 8, as Measured by OBP

Intervention	Participants (Count of Participants)
	AE(s)	SAE(s)	Hyperkalemia [potassium level >5.5 mmol/L]	Hyperkalemia [potassium level ≥6.0 mmol/L]	Hyponatremia [sodium level <130 and ≥125 mmol/L]	Hyponatremia [sodium level <135 mmol/L and ≥130mmol/L]
Eplerenone 50 mg BID	13	1	0	0	1	3
LCI699 0.25 mg BID	15	0	2	2	0	3
LCI699 0.5 mg Followed by LCI699 1 mg BID	8	0	0	0	0	7
LCI699 1 mg QD	15	0	0	0	0	2
Placebo	16	0	1	0	0	2

MSDBP response was defined as the percentage of participants with a MSDBP <90 mmHg or a >=10 mmHg reduction from baseline. MSDBP control was defined as the percentage of participants with a MSDBP <90 mmHg for non-diabetic participants and <80mHg for diabetic participants. (NCT00817635)
Timeframe: Week 8

Percentage of Participants With a MSSBP Response and MSSBP Control at Week 8, as Measured by Office Blood Pressure (OBP)

Article	Year
The Effect of Aldosterone on Cardiorenal and Metabolic Systems. International journal of molecular sciences, 2023, Mar-11, Volume: 24, Issue:6 Topics: Aldosterone; Cardiovascular Diseases; Essential Hypertension; Humans; Hyperaldosteronism; Hypertensi	2023
Primary aldosteronism is a public health issue: challenges and opportunities. Journal of human hypertension, 2020, Volume: 34, Issue:7 Topics: Aldosterone; Blood Pressure; Essential Hypertension; Humans; Hyperaldosteronism; Hypertension; Publi	2020
Excessive Catecholamine Secretion and the Activation of the Renin-Angiotensin-Aldosterone-System in Patients with Pheochromocytoma: A Single Center Experience and Overview of the Literature. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2017, Volume: 49, Issue:10 Topics: Adrenal Gland Neoplasms; Aldosterone; Catecholamines; Essential Hypertension; Female; Humans; Male;	2017
Aldosterone and Left Ventricular Remodeling. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2015, Volume: 47, Issue:13 Topics: Aldosterone; Essential Hypertension; Heart Ventricles; Humans; Hyperaldosteronism; Hypertension; Ven	2015
MECHANISMS IN ESSENTIAL HYPERTENSION. Diseases of the chest, 1964, Volume: 45 Topics: Aldosterone; Angiotensins; Catecholamines; Essential Hypertension; Guanethidine; Hypertension; Miner	1964
[METABOLIC DATA ON HYPERTENSION (ESSENTIAL HYPERTENSION)]. Lekarska veda v zahranici, 1964, Aug-21, Volume: 22 Topics: Adrenal Glands; Aldosterone; Angiotensins; Arteriosclerosis; Autonomic Nervous System Diseases; Cate	1964
[NEW DATA ON THE ETIOPATHOGENESIS OF ESSENTIAL ARTERIAL HYPERTENSION]. Studii si cercetari de medicina interna, 1965, Volume: 40 Topics: Aldosterone; Electrolytes; Essential Hypertension; Humans; Hypertension; Metabolism	1965

Article	Year
Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. Journal of hypertension, 2013, Volume: 31, Issue:10 Topics: Adolescent; Adrenal Glands; Adult; Aged; Aldosterone; Antihypertensive Agents; Biomarkers; Blood Pre	2013
Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. Journal of hypertension, 2013, Volume: 31, Issue:10 Topics: Adolescent; Adrenal Glands; Adult; Aged; Aldosterone; Antihypertensive Agents; Biomarkers; Blood Pre	2013
Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. Journal of hypertension, 2013, Volume: 31, Issue:10 Topics: Adolescent; Adrenal Glands; Adult; Aged; Aldosterone; Antihypertensive Agents; Biomarkers; Blood Pre	2013
Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. Journal of hypertension, 2013, Volume: 31, Issue:10 Topics: Adolescent; Adrenal Glands; Adult; Aged; Aldosterone; Antihypertensive Agents; Biomarkers; Blood Pre	2013
Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. Journal of hypertension, 2013, Volume: 31, Issue:10 Topics: Adolescent; Adrenal Glands; Adult; Aged; Aldosterone; Antihypertensive Agents; Biomarkers; Blood Pre	2013
Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. Journal of hypertension, 2013, Volume: 31, Issue:10 Topics: Adolescent; Adrenal Glands; Adult; Aged; Aldosterone; Antihypertensive Agents; Biomarkers; Blood Pre	2013
Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. Journal of hypertension, 2013, Volume: 31, Issue:10 Topics: Adolescent; Adrenal Glands; Adult; Aged; Aldosterone; Antihypertensive Agents; Biomarkers; Blood Pre	2013
Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. Journal of hypertension, 2013, Volume: 31, Issue:10 Topics: Adolescent; Adrenal Glands; Adult; Aged; Aldosterone; Antihypertensive Agents; Biomarkers; Blood Pre	2013
Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. Journal of hypertension, 2013, Volume: 31, Issue:10 Topics: Adolescent; Adrenal Glands; Adult; Aged; Aldosterone; Antihypertensive Agents; Biomarkers; Blood Pre	2013
Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. Journal of hypertension, 2013, Volume: 31, Issue:10 Topics: Adolescent; Adrenal Glands; Adult; Aged; Aldosterone; Antihypertensive Agents; Biomarkers; Blood Pre	2013
Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. Journal of hypertension, 2013, Volume: 31, Issue:10 Topics: Adolescent; Adrenal Glands; Adult; Aged; Aldosterone; Antihypertensive Agents; Biomarkers; Blood Pre	2013
Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. Journal of hypertension, 2013, Volume: 31, Issue:10 Topics: Adolescent; Adrenal Glands; Adult; Aged; Aldosterone; Antihypertensive Agents; Biomarkers; Blood Pre	2013
Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. Journal of hypertension, 2013, Volume: 31, Issue:10 Topics: Adolescent; Adrenal Glands; Adult; Aged; Aldosterone; Antihypertensive Agents; Biomarkers; Blood Pre	2013
Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. Journal of hypertension, 2013, Volume: 31, Issue:10 Topics: Adolescent; Adrenal Glands; Adult; Aged; Aldosterone; Antihypertensive Agents; Biomarkers; Blood Pre	2013
Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. Journal of hypertension, 2013, Volume: 31, Issue:10 Topics: Adolescent; Adrenal Glands; Adult; Aged; Aldosterone; Antihypertensive Agents; Biomarkers; Blood Pre	2013
Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. Journal of hypertension, 2013, Volume: 31, Issue:10 Topics: Adolescent; Adrenal Glands; Adult; Aged; Aldosterone; Antihypertensive Agents; Biomarkers; Blood Pre	2013
Marinobufagenin in essential hypertension and primary aldosteronism: a cardiotonic steroid with clinical and diagnostic implications. Clinical and experimental hypertension (New York, N.Y. : 1993), 2015, Volume: 37, Issue:2 Topics: Aldosterone; Blood Pressure; Bufanolides; Carotid Intima-Media Thickness; Essential Hypertension; Fe	2015
TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. Journal of hypertension, 2015, Volume: 33, Issue:6 Topics: Adult; Aged; Aldosterone; Antihypertensive Agents; Blood Pressure; Case-Control Studies; Dioxygenase	2015
Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study). Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia, 2016, Jun-20, Volume: 22, Issue:3 Topics: Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents;	2016

Article	Year
Modulation of 11β-hydroxysteroid dehydrogenase functions by the cloud of endogenous metabolites in a local microenvironment: The glycyrrhetinic acid-like factor (GALF) hypothesis. The Journal of steroid biochemistry and molecular biology, 2021, Volume: 214 Topics: 11-beta-Hydroxysteroid Dehydrogenases; Aldosterone; Animals; Blood Pressure; Corticosterone; Essenti	2021
Evaluation of Intra-Renal Stiffness in Patients with Primary Aldosteronism. High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2022, Volume: 29, Issue:1 Topics: Adult; Aged; Aldosterone; Essential Hypertension; Female; Humans; Hyperaldosteronism; Hypertension;	2022
A pilot study to evaluate the erythrocyte glycocalyx sensitivity to sodium as a marker for cellular salt sensitivity in hypertension. Journal of human hypertension, 2023, Volume: 37, Issue:4 Topics: Aldosterone; Blood Pressure; Erythrocytes; Essential Hypertension; Female; Glycocalyx; Humans; Hyper	2023
Radiomics utilization to differentiate nonfunctional adenoma in essential hypertension and functional adenoma in primary aldosteronism. Scientific reports, 2022, 05-25, Volume: 12, Issue:1 Topics: Adenoma; Adrenalectomy; Aldosterone; Essential Hypertension; Humans; Hyperaldosteronism; Retrospecti	2022
Divergent Characteristics of T-Cell Receptor Repertoire Between Essential Hypertension and Aldosterone-Producing Adenoma. Frontiers in immunology, 2022, Volume: 13 Topics: Adenoma; Aldosterone; Essential Hypertension; Humans; Hypertension; Receptors, Antigen, T-Cell; Reni	2022
Association between Vitamin D Deficiency and Levels of Renin and Angiotensin in Essential Hypertension. International journal of clinical practice, 2022, Volume: 2022 Topics: Adult; Aldosterone; Angiotensins; Asian People; Blood Pressure; Essential Hypertension; Female; Huma	2022
Circulating Plasma Concentrations of ACE2 in Primary Aldosteronism and Cardiovascular Outcomes. The Journal of clinical endocrinology and metabolism, 2022, 11-25, Volume: 107, Issue:12 Topics: Adrenalectomy; Aldosterone; Angiotensin-Converting Enzyme 2; Cardiovascular Diseases; Essential Hype	2022
Serum aldosterone effect on left ventricular structure and diastolic function in essential hypertension. Journal of clinical hypertension (Greenwich, Conn.), 2023, Volume: 25, Issue:2 Topics: Aldosterone; Diastole; Echocardiography; Essential Hypertension; Female; Humans; Hypertension; Hyper	2023
Aldosterone Synthase Inhibitors and the Treatment of Essential Hypertension. The Journal of clinical endocrinology and metabolism, 2023, Jul-14, Volume: 108, Issue:8 Topics: Aldosterone; Cytochrome P-450 CYP11B2; Essential Hypertension; Humans; Hyperaldosteronism; Hypertens	2023
KCNJ5 mutation is a predictor for recovery of endothelial function after adrenalectomy in patients with aldosterone-producing adenoma. Hypertension research : official journal of the Japanese Society of Hypertension, 2023, Volume: 46, Issue:9 Topics: Adenoma; Adrenalectomy; Aldosterone; Ankle Brachial Index; Essential Hypertension; G Protein-Coupled	2023
Central diastolic blood pressure, plasma aldosterone and uric acid are associated with microalbuminuria in essential hypertension: a case-control study. BMC cardiovascular disorders, 2023, 10-17, Volume: 23, Issue:1 Topics: Albuminuria; Aldosterone; Blood Pressure; Case-Control Studies; Essential Hypertension; Humans; Hype	2023
Renin-Angiotensin-Aldosterone System Triple-A Analysis for the Screening of Primary Aldosteronism. Hypertension (Dallas, Tex. : 1979), 2020, Volume: 75, Issue:1 Topics: Adult; Aldosterone; Angiotensin I; Angiotensin II; Essential Hypertension; Female; Humans; Hyperaldo	2020
The relationship of plasma renin, angiotensin, and aldosterone levels to blood pressure variability and target organ damage in children with essential hypertension. BMC cardiovascular disorders, 2020, 06-16, Volume: 20, Issue:1 Topics: Adolescent; Age Factors; Aldosterone; Angiotensins; Biomarkers; Blood Pressure; Child; Essential Hyp	2020
Associations Between Metabolic Profiles and Target-Organ Damage in Chinese Individuals With Primary Aldosteronism. Frontiers in endocrinology, 2020, Volume: 11 Topics: Adult; Aldosterone; Asian People; Case-Control Studies; China; Essential Hypertension; Female; Human	2020
Confirmatory testing of primary aldosteronism with saline infusion test and LC-MS/MS. European journal of endocrinology, 2021, Volume: 184, Issue:1 Topics: Adult; Aged; Aldosterone; Blood Chemical Analysis; Chromatography, Liquid; Cohort Studies; Diagnosis	2021
Correlation between serum microRNA-136 levels and RAAS biochemical markers in patients with essential hypertension. European review for medical and pharmacological sciences, 2020, Volume: 24, Issue:22 Topics: Adult; Aged; Aldosterone; Biomarkers; Essential Hypertension; Female; Humans; Male; MicroRNAs; Middl	2020
Growth differentiation factor 15 levels are similar in primary aldosteronism and essential hypertension and do not predict arterial inflammation. Journal of hypertension, 2021, 03-01, Volume: 39, Issue:3 Topics: Aldosterone; Arteritis; Essential Hypertension; Growth Differentiation Factor 15; Humans; Hyperaldos	2021
Novel chemiluminescent immunoassay to measure plasma aldosterone and plasma active renin concentrations for the diagnosis of primary aldosteronism. Journal of human hypertension, 2022, Volume: 36, Issue:1 Topics: Aldosterone; Essential Hypertension; Humans; Hyperaldosteronism; Hypertension; Radioimmunoassay; Ren	2022
Hemodynamic and Non-Hemodynamic Components of Cardiac Remodeling in Primary Aldosteronism. Frontiers in endocrinology, 2021, Volume: 12 Topics: Adrenalectomy; Adrenocortical Adenoma; Adult; Aldosterone; Blood Pressure; Echocardiography; Essenti	2021
Aldosterone hyperreactivity to acute psychosocial stress induction in men with essential hypertension. Hormones and behavior, 2021, Volume: 134 Topics: Aldosterone; Blood Pressure; Essential Hypertension; Humans; Hypertension; Male; Stress, Psychologic	2021
Evaluation of Abdominal Computed Tomography Scans for Differentiating the Discrepancies in Abdominal Adipose Tissue Between Two Major Subtypes of Primary Aldosteronism. Frontiers in endocrinology, 2021, Volume: 12 Topics: Abdominal Fat; Adult; Aged; Aldosterone; Databases, Factual; Essential Hypertension; Female; Humans;	2021
Lipid Profiles in Primary Aldosteronism Compared with Essential Hypertension: Propensity-Score Matching Study. Endocrinology and metabolism (Seoul, Korea), 2021, Volume: 36, Issue:4 Topics: Aldosterone; Essential Hypertension; Humans; Hyperaldosteronism; Hypertension; Lipids; Retrospective	2021
Aldosterone a Relevant Factor in the Beginning and Evolution of Arterial Hypertension. American journal of hypertension, 2017, 05-01, Volume: 30, Issue:5 Topics: Aldosterone; Essential Hypertension; Humans; Hypertension; Renin	2017
Plasma renin activity to plasma aldosterone concentration ratio correlates with night-time and pulse pressures in essential hypertensive patients treated with angiotensin-converting enzyme inhibitors/AT1 blockers. Journal of hypertension, 2017, Volume: 35, Issue:11 Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biom	2017
Aldosterone induces left ventricular subclinical systolic dysfunction: a strain imaging study. Journal of hypertension, 2018, Volume: 36, Issue:2 Topics: Adult; Aged; Aldosterone; Echocardiography; Essential Hypertension; Female; Heart; Humans; Hyperaldo	2018
Inflammation and Fibrosis in Perirenal Adipose Tissue of Patients With Aldosterone-Producing Adenoma. Endocrinology, 2018, 01-01, Volume: 159, Issue:1 Topics: 3T3-L1 Cells; Adenoma; Adipocytes, Brown; Adipogenesis; Adipokines; Adrenalectomy; Aldosterone; Anim	2018
Confirmatory Tests for the Diagnosis of Primary Aldosteronism: A Prospective Diagnostic Accuracy Study. Hypertension (Dallas, Tex. : 1979), 2018, Volume: 71, Issue:1 Topics: Adrenal Cortex; Adrenal Cortex Function Tests; Adult; Aldosterone; Captopril; Clinical Chemistry Tes	2018
Evaluation of the Saline Infusion Test and the Captopril Challenge Test in Chinese Patients With Primary Aldosteronism. The Journal of clinical endocrinology and metabolism, 2018, 03-01, Volume: 103, Issue:3 Topics: Adrenal Cortex Function Tests; Adult; Aldosterone; Asian People; Captopril; Essential Hypertension;	2018
IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis. Cardiovascular research, 2018, 04-01, Volume: 114, Issue:5 Topics: Adult; Aldosterone; Animals; Cardiomegaly; Case-Control Studies; Cells, Cultured; Collagen; Cytokine	2018
Criteria for diagnosing primary aldosteronism on the basis of liquid chromatography-tandem mass spectrometry determinations of plasma aldosterone concentration. Journal of hypertension, 2018, Volume: 36, Issue:7 Topics: Adolescent; Adult; Aged; Aldosterone; Case-Control Studies; Chromatography, Liquid; Essential Hypert	2018
Untangling Essential Hypertension: The Potential Roles of Aldosterone and Atrial Natriuretic Peptide. Mayo Clinic proceedings, 2018, Volume: 93, Issue:8 Topics: Aldosterone; Antihypertensive Agents; Atrial Natriuretic Factor; Essential Hypertension; Humans; Hyp	2018
Obesity as a Key Factor Underlying Idiopathic Hyperaldosteronism. The Journal of clinical endocrinology and metabolism, 2018, 12-01, Volume: 103, Issue:12 Topics: Adult; Aldosterone; Cross-Sectional Studies; Diabetes Mellitus; Dyslipidemias; Essential Hypertensio	2018
Microvascular endothelial function is impaired in patients with idiopathic hyperaldosteronism. Hypertension research : official journal of the Japanese Society of Hypertension, 2018, Volume: 41, Issue:11 Topics: Adult; Aldosterone; Blood Pressure; Endothelium, Vascular; Essential Hypertension; Female; Humans; H	2018
PTH Modulation by Aldosterone and Angiotensin II is Blunted in Hyperaldosteronism and Rescued by Adrenalectomy. The Journal of clinical endocrinology and metabolism, 2019, 09-01, Volume: 104, Issue:9 Topics: Adenoma; Adrenal Hyperplasia, Congenital; Adrenalectomy; Aldosterone; Angiotensin II; Antihypertensi	2019
Subclinical atherosclerosis due to increase of plasma aldosterone concentrations in essential hypertensive individuals. Journal of hypertension, 2019, Volume: 37, Issue:11 Topics: Adult; Aldosterone; Ankle Brachial Index; Atherosclerosis; Biomarkers; Carotid Intima-Media Thicknes	2019
Aldosterone Induces Vascular Damage. Hypertension (Dallas, Tex. : 1979), 2019, Volume: 74, Issue:3 Topics: Adult; Aldosterone; Antihypertensive Agents; Area Under Curve; Arterial Pressure; Cohort Studies; Cr	2019
Urinary sodium excretion is the main determinant of mineralocorticoid excretion rates in patients with chronic kidney disease. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2013, Volume: 28, Issue:6 Topics: Aldosterone; Cohort Studies; Corticosterone; Cross-Sectional Studies; Essential Hypertension; Female	2013
Aldosterone levels and inflammatory stimulation in essential hypertensive patients. Journal of human hypertension, 2013, Volume: 27, Issue:9 Topics: Adult; Aged; Aldosterone; Biomarkers; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; C	2013
Serum dehydroepiandrosterone sulfate concentration is lower in women with primary aldosteronism. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2015, Volume: 16, Issue:1 Topics: Adenoma; Adult; Aged; Aldosterone; Cholesterol, HDL; Creatinine; Dehydroepiandrosterone Sulfate; Ess	2015
Bone health and aldosterone excess. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2013, Volume: 24, Issue:11 Topics: Absorptiometry, Photon; Adult; Aged; Aldosterone; Bone Density; Calcium; Essential Hypertension; Fem	2013
Comparison of 24-h urinary aldosterone level and random urinary aldosterone-to-creatinine ratio in the diagnosis of primary aldosteronism. PloS one, 2013, Volume: 8, Issue:6 Topics: Adenoma; Adrenal Gland Neoplasms; Adult; Aldosterone; Creatinine; Essential Hypertension; Female; Hu	2013
Quantification of urinary 18-hydroxycortisol using LC-MS/MS. Annals of clinical biochemistry, 2013, Volume: 50, Issue:Pt 5 Topics: Adenoma; Adrenal Gland Neoplasms; Aldosterone; Biomarkers, Tumor; Chromatography, Liquid; Essential	2013
[Analysis of characteristics of renin, aldosterone and aldosterone/renin ratio in patients with aldosterone-producing adenoma]. Zhonghua yi xue za zhi, 2013, Nov-12, Volume: 93, Issue:42 Topics: Adrenal Gland Neoplasms; Adult; Aldosterone; Case-Control Studies; Essential Hypertension; Female; H	2013
Measurement of plasma renin concentration instead of plasma renin activity decreases the positive aldosterone-to-renin ratio tests in treated patients with essential hypertension. Journal of hypertension, 2014, Volume: 32, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aldosterone; Antihypertensive Agents; Blood Chemical Ana	2014
[Influence factors of salt-sensitive hypertension and responses of blood pressure and urinary sodium and potassium excretion to acute oral saline loading among essential hypertensive patients]. Zhonghua xin xue guan bing za zhi, 2013, Volume: 41, Issue:12 Topics: Adult; Aged; Aldosterone; Blood Pressure; Electrolytes; Essential Hypertension; Female; Humans; Hype	2013
Aldosterone to active Renin ratio as screening test for primary aldosteronism: reproducibility and influence of orthostasis and salt loading. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2014, Volume: 46, Issue:6 Topics: Aldosterone; Cohort Studies; Dizziness; Essential Hypertension; Female; Humans; Hyperaldosteronism;	2014
Primary aldosteronism and essential hypertension: assessment of cardiovascular risk at diagnosis and after treatment. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2014, Volume: 24, Issue:5 Topics: Adult; Aged; Aldosterone; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Essential Hyperten	2014
Association between urine aldosterone and diastolic function in patients with primary aldosteronism and essential hypertension. Clinical biochemistry, 2014, Volume: 47, Issue:13-14 Topics: Adult; Aldosterone; Echocardiography; Essential Hypertension; Female; Humans; Hyperaldosteronism; Hy	2014
Oxidative stress in patients affected by primary aldosteronism. Journal of hypertension, 2014, Volume: 32, Issue:10 Topics: Adenoma; Adrenalectomy; Adult; Aged; Aldosterone; Essential Hypertension; Female; Humans; Hyperaldos	2014
Decreased plasma prorenin levels in primary aldosteronism: potential diagnostic implications. Journal of hypertension, 2015, Volume: 33, Issue:1 Topics: Adenoma; Adult; Aldosterone; Cohort Studies; Essential Hypertension; Female; Humans; Hyperaldosteron	2015
Plasma aldosterone and left ventricular diastolic function in treatment-naïve patients with hypertension: tissue-Doppler imaging study. Hypertension (Dallas, Tex. : 1979), 2015, Volume: 65, Issue:6 Topics: Adult; Aldosterone; Analysis of Variance; Case-Control Studies; Chi-Square Distribution; Diastole; E	2015
Stress-induced Aldosterone Hyper-Secretion in a Substantial Subset of Patients With Essential Hypertension. The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:8 Topics: Adenoma; Adrenal Gland Neoplasms; Adrenocorticotropic Hormone; Aldosterone; Case-Control Studies; Cy	2015
[The inversion of concepts about biological role of system rennin-angiotensin II- aldosterone and functions of arterial tension as a metabolism regulator]. Klinicheskaia laboratornaia diagnostika, 2015, Volume: 60, Issue:2 Topics: Aldosterone; Angiotensin II; Arterial Pressure; Arteries; Chymosin; Essential Hypertension; Humans;	2015
Obstructive Sleep Apnea Using Watch-PAT 200 Is Independently Associated With an Increase in Morning Blood Pressure Surge in Never-Treated Hypertensive Patients. Journal of clinical hypertension (Greenwich, Conn.), 2015, Volume: 17, Issue:9 Topics: Adult; Aldosterone; Blood Pressure; Blood Pressure Determination; Blood Pressure Monitoring, Ambulat	2015
Prevalence of Liddle Syndrome Among Young Hypertension Patients of Undetermined Cause in a Chinese Population. Journal of clinical hypertension (Greenwich, Conn.), 2015, Volume: 17, Issue:11 Topics: Adult; Aldosterone; China; Diagnostic Errors; Essential Hypertension; Female; Humans; Hypertension;	2015
Circulating tissue inhibitor of matrix metalloproteinase-1 is associated with aldosterone-induced diastolic dysfunction. Journal of hypertension, 2015, Volume: 33, Issue:9 Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Adenoma; Adult; Aldosterone; Diastole; Echoc	2015
Clinical validation for the aldosterone-to-renin ratio and aldosterone suppression testing using simultaneous fully automated chemiluminescence immunoassays. Journal of hypertension, 2015, Volume: 33, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Blood Pressure; Essential Hypertension; Female; Humans;	2015
Factors affecting parathyroid hormone levels in different types of primary aldosteronism. Clinical endocrinology, 2016, Volume: 85, Issue:2 Topics: Adenoma; Adrenal Hyperplasia, Congenital; Adrenalectomy; Adult; Aldosterone; Calcium; Essential Hype	2016
[Evaluation of the ratio of plasma aldosterone to rennin concentration measured by an automated chemiluminescent immunoassay in screening for primary aldosteronism]. Zhonghua nei ke za zhi, 2016, Volume: 55, Issue:1 Topics: Aldosterone; Area Under Curve; Case-Control Studies; Chymosin; Essential Hypertension; Humans; Hyper	2016
[An evaluation of plasma aldosterone-to-active-renin ratio in different postures in combination with aldosterone concentration in the diagnosis of aldosteronoma]. Zhonghua nei ke za zhi, 2016, Volume: 55, Issue:6 Topics: Aldosterone; Asian People; China; Essential Hypertension; Humans; Hyperaldosteronism; Hypertension;	2016
Aldosterone-Renin Ratio and Side-Selective Renal Perfusion in Essential Hypertension. American journal of hypertension, 2016, 11-01, Volume: 29, Issue:11 Topics: Aldosterone; Blood Pressure; Essential Hypertension; Humans; Hypertension; Kidney; Renin; Renin-Angi	2016
Endogenous ouabain and aldosterone are coelevated in the circulation of patients with essential hypertension. Journal of hypertension, 2016, Volume: 34, Issue:10 Topics: Adult; Aldosterone; Blood Pressure; Essential Hypertension; Female; Humans; Hyperaldosteronism; Hype	2016
Cortisol/cortisone ratio and matrix metalloproteinase-9 activity are associated with pediatric primary hypertension. Journal of hypertension, 2016, Volume: 34, Issue:9 Topics: Adiponectin; Adolescent; Aldosterone; Blood Pressure; Body Mass Index; C-Reactive Protein; Child; Ch	2016
Cholecalciferol treatment downregulates renin-angiotensin system and improves endothelial function in essential hypertensive patients with hypovitaminosid D. Journal of hypertension, 2016, Volume: 34, Issue:11 Topics: Adult; Aldosterone; Angiotensin II; Blood Pressure; Cardiovascular Diseases; Cholecalciferol; Endoth	2016
Increased urinary excretion of the epithelial Na channel activator prostasin in patients with primary aldosteronism. Journal of hypertension, 2017, Volume: 35, Issue:2 Topics: Adult; Aldosterone; Biomarkers; Blood Pressure; Epithelial Sodium Channels; Essential Hypertension;	2017
Role of adrenocorticotropic hormone in essential hypertension and primary aldosteronism. Journal of clinical hypertension (Greenwich, Conn.), 2017, Volume: 19, Issue:3 Topics: Adenoma; Adrenocorticotropic Hormone; Aldosterone; Blood Pressure; Essential Hypertension; Humans; H	2017
Plasma adrenocorticotropic hormone but not aldosterone is correlated with blood pressure in patients with aldosterone-producing adenomas. Journal of clinical hypertension (Greenwich, Conn.), 2017, Volume: 19, Issue:3 Topics: Adenoma; Adrenocorticotropic Hormone; Adult; Aged; Aldosterone; Blood Pressure; Essential Hypertensi	2017
Plasma aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism. Journal of hypertension, 2017, Volume: 35, Issue:5 Topics: Adult; Aged; Aldosterone; Blood Pressure; Cardiovascular Diseases; Cross-Sectional Studies; Essentia	2017
Plasma and urinary metanephrines determined by an enzyme immunoassay, but not serum chromogranin A for the diagnosis of pheochromocytoma in patients with adrenal mass. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2012, Volume: 120, Issue:8 Topics: Adrenal Gland Neoplasms; Adrenocortical Adenoma; Adult; Aldosterone; Chromogranin A; Diagnosis, Diff	2012
Association of elevated plasma aldosterone-to-renin ratio with future cardiovascular events in patients with essential hypertension. Journal of hypertension, 2012, Volume: 30, Issue:12 Topics: Adult; Aged; Aldosterone; Asian People; Cardiovascular Diseases; Cohort Studies; Essential Hypertens	2012
Cholecalciferol administration blunts the systemic renin-angiotensin system in essential hypertensives with hypovitaminosis D. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2014, Volume: 15, Issue:1 Topics: Adult; Aged; Aldosterone; Angiotensin II; Cholecalciferol; Essential Hypertension; Female; Humans; H	2014
Aldosteronism and hypertension: the influence of complete adrenalectomy upon essential hypertension in a child. Pediatrics, 1959, Volume: 23, Issue:6 Topics: Adrenalectomy; Aldosterone; Child; Essential Hypertension; Humans; Hyperaldosteronism; Hypertension;	1959
Aldosterone excretion in essential hypertension. The Journal of clinical endocrinology and metabolism, 1960, Volume: 20 Topics: Aldosterone; Biological Transport; Body Fluids; Essential Hypertension; Humans; Hypertension	1960
[Urinary excretion of aldosterone in essential hypertension. Investigations by a chemical method]. Folia endocrinologica; mensile di incretologia e incretoterapia, 1960, Volume: 13 Topics: Aldosterone; Body Fluids; Essential Hypertension; Humans; Hypertension	1960
[Conn's syndrome and essential arterial hypertension]. Il Progresso medico, 1960, Aug-15, Volume: 16 Topics: Aldosterone; Essential Hypertension; Humans; Hyperaldosteronism; Hypertension	1960
Essential hypertension and aldosterone. Circulation, 1961, Volume: 23 Topics: Aldosterone; Essential Hypertension; Humans; Hypertension	1961
[Natruresis and aldosterone excretion in essential hypertension]. Schweizerische medizinische Wochenschrift, 1959, Apr-04, Volume: 89 Topics: Aldosterone; Biological Transport; Body Fluids; Essential Hypertension; Humans; Hypertension; Sodium	1959
Surgical treatment of hypertension -- primary aldosteronism. A review of 13 cases. The New England journal of medicine, 1962, 01-25, Volume: 266 Topics: Adrenal Cortex; Adrenal Cortex Neoplasms; Aldosterone; Essential Hypertension; Humans; Hyperaldoster	1962
Effect of chlorothiazide upon aldosterone excretion and sodium and potassium balance in essential hypertension. The Journal of laboratory and clinical medicine, 1962, Volume: 60 Topics: Aldosterone; Body Fluids; Chlorothiazide; Essential Hypertension; Humans; Hypertension; Potassium; S	1962
Influence of alterations in sodium intake on urinary aldosterone response to corticotropin in normal individuals and patients with essential hypertension. Metabolism: clinical and experimental, 1962, Volume: 11 Topics: Adrenocorticotropic Hormone; Aldosterone; Diet; Essential Hypertension; Humans; Hypertension; Nutrit	1962
Humoral factors in essential hypertension. Verhandlungen der Deutschen Gesellschaft fur Kreislaufforschung, 1963, Volume: 28 Topics: Aldosterone; Essential Hypertension; Humans; Hypertension; Renin	1963
[Intervention of aldosterone and electrolytes in the pathogenesis of essential hypertension]. Folia endocrinologica; mensile di incretologia e incretoterapia, 1962, Volume: 15 Topics: Aldosterone; Electrolytes; Essential Hypertension; Humans; Hyperaldosteronism; Hypertension; Sodium;	1962
BLOOD VOLUME, TOTAL BODY WATER AND ALDOSTERONE EXCRETION IN ESSENTIAL HYPERTENSION. Clinical science, 1964, Volume: 26 Topics: Aldosterone; Blood Volume; Blood Volume Determination; Body Fluids; Body Water; Chromium Isotopes; E	1964
Effects of an acute salt load in a case of primary hyperaldo-steronism before and nine months after surgical cure: comparison with normal subjects and patients with essential hypertension before and after reduction of their elevated pressure with drug tre The Journal of laboratory and clinical medicine, 1959, Volume: 54 Topics: Aldosterone; Essential Hypertension; Humans; Hypertension; Sodium Chloride; Sodium Chloride, Dietary	1959
[Contribution to the treatment of essential hypertension.(Control of blood pressure, active blood volume, venous pressure, circulation time and mineral metabolism after Repicin and spirolactone medication)]. Munchener medizinische Wochenschrift (1950), 1962, Feb-02, Volume: 104 Topics: Aldosterone; Blood Circulation Time; Blood Pressure; Blood Pressure Determination; Blood Volume; Chl	1962

aldosterone and Hypertension, Essential

Research Excerpts

Research

Studies (96)

Authors

Clinical Trials (8)

Trial Overview

Trial Outcomes

Apparent Terminal Half-life (T1/2) of LCI699

Area Under the Concentration Time Curve From Time 0 to 8 Hours Post LCI699 Administration (AUC0-8)

Area Under the Concentration Time Curve Over the Dosing Interval (AUC0-τ) for LCI699

LCI699 Plasma Concentration Post LCI699 Administration at Day 7

Maximum Plasma Concentration (Cmax) of LCI699

Maximum Tolerated Dose (MTD) of LCI699 With Respect to Effect on the Adrenocorticotropic Hormone (ACTH)-Stimulated Cortisol Response Following ACTH Stimulation in Hypertensive Participants

Number of Participants With Adverse Event (AEs)

Time of Maximum Plasma Concentration (Tmax) of LCI699

LCI699 Exposure-response Relationship on Cortisol Levels Following ACTH Stimulation in Hypertensive Participants

Percentage of Participants With a Mean Sitting Diastolic Blood Pressure (MSDBP) Response and MSDBP Control at Week 6 LOCF, as Measured by OBP

Percentage of Participants With a Mean Sitting Systolic Blood Pressure (MSSBP) Response and MSSBP Control at Week 6 Last Observation Carried Forward (LOCF), as Measured by Office Blood Pressure (OBP)

Core Period: Change From Baseline in Mean 24 Hour Ambulatory DBP at Week 8, as Measured by ABPM

Core Period: Change From Baseline in Mean 24 Hour Ambulatory SBP at Week 8 as Measured by Ambulatory Blood Pressure Monitoring (ABPM)

Core Period: Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8 Last Observation Carried Forward (LOCF), as Measured by Office Blood Pressure (OBP)

Core Period: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8 LOCF, as Measured by OBP

Core Period: Change From Baseline in Plasma Aldosterone Levels at Week 8

Core Period: Change From Baseline in Plasma Cortisol Levels by Adrenocorticotropic Hormone (ACTH) Stimulation Test

Core Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSDBP at Week 8

Core Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSSBP at Week 8

Withdrawal Period: Change From Week 8 to Week 9 in MSDBP at Week 9, as Measured by OBP

Withdrawal Period: Change From Week 8 to Week 9 in MSSBP at Week 9 as Measured by OBP

Core Period: Number of Participants With Adverse Event (AEs), Serious Adverse Events (SAEs), and Deaths

Core Period: Percentage of Participants With a MSDBP Response and MSDBP Control at Week 8 LOCF

Core Period: Percentage of Participants With a MSSBP Response and MSSBP Control at Week 8 LOCF

Core Period: Trough to Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory DBP at Week 8

Core Period: Trough to Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory SBP at Week 8

Change From Baseline in MSDBP at Week 8 LOCF

Change From Baseline in MSSBP at Week 8 Last Observation Carried Forward (LOCF)

Dose/Exposure BP Response Relationship of LCI699, as Measured by Change From Baseline in MSDBP at Week 8

Dose/Exposure BP Response Relationship of LCI699, as Measured by Change From Baseline in MSSBP at Week 8

Number of Participants With Cortisol Levels Below 500 Nmol/L at 1 Hour After Adrenocorticotropic Hormone (ACTH) Injection at Week 8

Percent Change From Baseline in RAAS Biomarker: Active Renin (ARC) in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF

Percent Change From Baseline in RAAS Biomarker: Plasma Renin Activity (PRA) in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF

Percent Change From Baseline in RAAS Biomarker: Ratio of PA to PRA in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF

Percent Change From Baseline in Renin-Angiotensin-Aldosterone-System (RAAS) Biomarker: Plasma Aldosterone (PA) in LCI699 Compared to Eplerenone 50 mg at Week 8 LOCF

Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime DBP in LCI699 1mg QD Versus LCI699 0.5mg BID Arm at Week 4, as Measured by ABPM

Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime Diastolic Blood Pressure (DBP) at Week 8 LOCF, as Measured by ABPM

Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime SBP in LCI699 1mg QD Versus LCI699 0.5mg BID Arm at Week 4, as Measured by ABPM

Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime Systolic Blood Pressure (SBP) at Week 8 LOCF, as Measured by Ambulatory Blood Pressure Measurement (ABPM)

Number of Participants With Adverse Event (AEs), Serious Adverse Events (SAEs), Hyperkalemia, and Hyponatremia

Percentage of Participants With a MSDBP Response and MSDBP Control at Week 8, as Measured by OBP

Percentage of Participants With a MSSBP Response and MSSBP Control at Week 8, as Measured by Office Blood Pressure (OBP)

Reviews

Trials

Other Studies